BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med. 2008;359:1932-1940. [PMID: 18971494 DOI: 10.1056/nejmra0707500] [Cited by in Crossref: 954] [Cited by in F6Publishing: 451] [Article Influence: 68.1] [Reference Citation Analysis]
Number Citing Articles
1 Daneman N, Stukel TA, Ma X, Vermeulen M, Guttmann A. Reduction in Clostridium difficile infection rates after mandatory hospital public reporting: findings from a longitudinal cohort study in Canada. PLoS Med 2012;9:e1001268. [PMID: 22815656 DOI: 10.1371/journal.pmed.1001268] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
2 Corbellini S, Piccinelli G, De Francesco MA, Ravizzola G, Bonfanti C. Molecular epidemiology of Clostridium difficile strains from nosocomial-acquired infections. Folia Microbiol (Praha) 2014;59:173-9. [PMID: 24081935 DOI: 10.1007/s12223-013-0281-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Huang H, Nord CE. Can metronidazole still be used for treatment of Clostridium difficile infections? Curr Infect Dis Rep 2009;11:3-6. [PMID: 19094818 DOI: 10.1007/s11908-009-0001-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
4 Heinlen L, Ballard JD. Clostridium difficile infection. Am J Med Sci. 2010;340:247-252. [PMID: 20697257 DOI: 10.1097/maj.0b013e3181e939d8] [Cited by in Crossref: 89] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
5 Hotinger JA, Morris ST, May AE. The Case against Antibiotics and for Anti-Virulence Therapeutics. Microorganisms 2021;9:2049. [PMID: 34683370 DOI: 10.3390/microorganisms9102049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Beal EW, Bass R, Harzman AE. Two Patients with Fulminant Clostridium difficile Enteritis Who Had Not Undergone Total Colectomy: A Case Series and Review of the Literature. Case Rep Surg 2015;2015:957257. [PMID: 26682082 DOI: 10.1155/2015/957257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Di Bella S, Musso M, Cataldo MA, Meledandri M, Bordi E, Capozzi D, Cava MC, Chiaradonna P, Prignano G, Petrosillo N. Clostridium difficile infection in Italian urban hospitals: data from 2006 through 2011. BMC Infect Dis 2013;13:146. [PMID: 23522431 DOI: 10.1186/1471-2334-13-146] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
8 Koon HW, Shih DQ, Hing TC, Yoo JH, Ho S, Chen X, Kelly CP, Targan SR, Pothoulakis C. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother 2013;57:3214-23. [PMID: 23629713 DOI: 10.1128/AAC.02633-12] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
9 Stampfer L, Deutschmann A, Dür E, Eitelberger FG, Fürpass T, Gorkiewicz G, Heinz-Erian P, Heller I, Herzog K, Hopfer B, Kerbl R, Klug E, Krause R, Leitner E, Mache C, Müller T, Pansy J, Pocivalnik M, Scheuba E, Schneditz G, Schweintzger G, Sterniczky E, Zechner E, Hauer AC, Högenauer C, Hoffmann KM. Causes of hematochezia and hemorrhagic antibiotic-associated colitis in children and adolescents. Medicine (Baltimore) 2017;96:e7793. [PMID: 28816966 DOI: 10.1097/MD.0000000000007793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shogbesan O, Poudel DR, Victor S, Jehangir A, Fadahunsi O, Shogbesan G, Donato A. A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients. Can J Gastroenterol Hepatol 2018;2018:1394379. [PMID: 30246002 DOI: 10.1155/2018/1394379] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
11 Schwan C, Kruppke AS, Nölke T, Schumacher L, Koch-Nolte F, Kudryashev M, Stahlberg H, Aktories K. Clostridium difficile toxin CDT hijacks microtubule organization and reroutes vesicle traffic to increase pathogen adherence. Proc Natl Acad Sci U S A 2014;111:2313-8. [PMID: 24469807 DOI: 10.1073/pnas.1311589111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
12 Pamer EG. Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns. Mucosal Immunol. 2014;7:210-214. [PMID: 24399149 DOI: 10.1038/mi.2013.117] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
13 Jank T, Bogdanović X, Wirth C, Haaf E, Spoerner M, Böhmer KE, Steinemann M, Orth JH, Kalbitzer HR, Warscheid B, Hunte C, Aktories K. A bacterial toxin catalyzing tyrosine glycosylation of Rho and deamidation of Gq and Gi proteins. Nat Struct Mol Biol 2013;20:1273-80. [PMID: 24141704 DOI: 10.1038/nsmb.2688] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
14 Katzianer DS, Yano T, Rubin H, Zhu J. A high-throughput small-molecule screen to identify a novel chemical inhibitor of Clostridium difficile. Int J Antimicrob Agents 2014;44:69-73. [PMID: 24837414 DOI: 10.1016/j.ijantimicag.2014.03.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
15 Hunter P. The return of the phage. EMBO Rep 2011;13:20-3. [PMID: 22134545 DOI: 10.1038/embor.2011.234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Shen A. Autoproteolytic activation of bacterial toxins. Toxins (Basel) 2010;2:963-77. [PMID: 22069620 DOI: 10.3390/toxins2050963] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
17 Fuentes S, van Nood E, Tims S, Heikamp-de Jong I, ter Braak CJ, Keller JJ, Zoetendal EG, de Vos WM. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J. 2014;8:1621-1633. [PMID: 24577353 DOI: 10.1038/ismej.2014.13] [Cited by in Crossref: 125] [Cited by in F6Publishing: 109] [Article Influence: 15.6] [Reference Citation Analysis]
18 Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol 2016;29:147-54. [PMID: 27065726 DOI: 10.20524/aog.2016.0006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
19 Bouillaut L, McBride S, Sorg JA, Schmidt DJ, Suarez JM, Tzipori S, Mascio C, Chesnel L, Sonenshein AL. Effects of surotomycin on Clostridium difficile viability and toxin production in vitro. Antimicrob Agents Chemother 2015;59:4199-205. [PMID: 25941230 DOI: 10.1128/AAC.00275-15] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
20 Hammond EN, Donkor ES. Antibacterial effect of Manuka honey on Clostridium difficile. BMC Res Notes 2013;6:188. [PMID: 23651562 DOI: 10.1186/1756-0500-6-188] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
21 Adams CM, Eckenroth BE, Putnam EE, Doublié S, Shen A. Structural and functional analysis of the CspB protease required for Clostridium spore germination. PLoS Pathog 2013;9:e1003165. [PMID: 23408892 DOI: 10.1371/journal.ppat.1003165] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 8.9] [Reference Citation Analysis]
22 Hsu CH, Schelwies M, Enck S, Huang LY, Huang SH, Chang YF, Cheng TJ, Cheng WC, Wong CH. Iminosugar C-glycoside analogues of α-D-GlcNAc-1-phosphate: synthesis and bacterial transglycosylase inhibition. J Org Chem 2014;79:8629-37. [PMID: 25137529 DOI: 10.1021/jo501340s] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
23 Ajami NJ, Cope JL, Wong MC, Petrosino JF, Chesnel L. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice. Antimicrob Agents Chemother 2018;62:e02112-17. [PMID: 29463537 DOI: 10.1128/AAC.02112-17] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
24 Mulvey MR, Boyd DA, Gravel D, Hutchinson J, Kelly S, McGeer A, Moore D, Simor A, Suh KN, Taylor G, Weese JS, Miller M; Canadian Nosocomial Infection Surveillance Program. Hypervirulent Clostridium difficile strains in hospitalized patients, Canada. Emerg Infect Dis 2010;16:678-81. [PMID: 20350386 DOI: 10.3201/eid1604.091152] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
25 Lee CH, Chai J, Hammond K, Jeon SR, Patel Y, Goldeh C, Kim P. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure. Eur J Clin Microbiol Infect Dis 2019;38:1731-5. [PMID: 31165961 DOI: 10.1007/s10096-019-03602-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
26 Tang C, Cui L, Xu Y, Xie L, Sun P, Liu C, Xia W, Liu G. The incidence and drug resistance of Clostridium difficile infection in Mainland China: a systematic review and meta-analysis. Sci Rep 2016;6:37865. [PMID: 27897206 DOI: 10.1038/srep37865] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
27 Carter RR, Sun J, Jump RL. A Survey and Analysis of the American Public's Perceptions and Knowledge About Antibiotic Resistance. Open Forum Infect Dis 2016;3:ofw112. [PMID: 27382598 DOI: 10.1093/ofid/ofw112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
28 Ballard TE, Wang X, Olekhnovich I, Koerner T, Seymour C, Salamoun J, Warthan M, Hoffman PS, Macdonald TL. Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity. ChemMedChem 2011;6:362-77. [PMID: 21275058 DOI: 10.1002/cmdc.201000475] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
29 Feuerstadt P, Hong SJ, Brandt LJ. Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection. Dig Dis Sci 2020;65:632-8. [DOI: 10.1007/s10620-019-05804-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Taur Y, Pamer EG. Harnessing microbiota to kill a pathogen: Fixing the microbiota to treat Clostridium difficile infections. Nat Med 2014;20:246-7. [PMID: 24603796 DOI: 10.1038/nm.3492] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
31 Falcone M, Russo A, Iraci F, Carfagna P, Goldoni P, Vullo V, Venditti M. Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection. Antimicrob Agents Chemother 2016;60:252-7. [PMID: 26482315 DOI: 10.1128/AAC.01927-15] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
32 Kullar R, Tran MN, Goldstein EJC. Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI). J Exp Pharmacol 2020;12:371-84. [PMID: 33116952 DOI: 10.2147/JEP.S242959] [Reference Citation Analysis]
33 Hung YP, Lee JC, Lin HJ, Liu HC, Wu YH, Tsai PJ, Ko WC. Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection. Antibiotics (Basel) 2015;4:216-29. [PMID: 27025622 DOI: 10.3390/antibiotics4020216] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
34 Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD, Wehland J, Aktories K. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009;5:e1000626. [PMID: 19834554 DOI: 10.1371/journal.ppat.1000626] [Cited by in Crossref: 233] [Cited by in F6Publishing: 211] [Article Influence: 17.9] [Reference Citation Analysis]
35 Nam HJ, Kang JK, Kim SK, Ahn KJ, Seok H, Park SJ, Chang JS, Pothoulakis C, Lamont JT, Kim H. Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation. J Biol Chem 2010;285:32888-96. [PMID: 20696758 DOI: 10.1074/jbc.M110.162743] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
36 Shen A, Lupardus PJ, Gersch MM, Puri AW, Albrow VE, Garcia KC, Bogyo M. Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins. Nat Struct Mol Biol 2011;18:364-71. [PMID: 21317893 DOI: 10.1038/nsmb.1990] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
37 Golan Y, Epstein L. Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea. Therap Adv Gastroenterol 2012;5:395-402. [PMID: 23152733 DOI: 10.1177/1756283X12461294] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
38 Weingarden AR, Chen C, Zhang N, Graiziger CT, Dosa PI, Steer CJ, Shaughnessy MK, Johnson JR, Sadowsky MJ, Khoruts A. Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection. J Clin Gastroenterol 2016;50:624-30. [PMID: 26485102 DOI: 10.1097/MCG.0000000000000427] [Cited by in Crossref: 54] [Cited by in F6Publishing: 31] [Article Influence: 10.8] [Reference Citation Analysis]
39 Yang Z, Shi L, Yu H, Zhang Y, Chen K, Saint Fleur A, Bai G, Feng H. Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection. Pathog Dis 2016;74:ftw078. [PMID: 27502696 DOI: 10.1093/femspd/ftw078] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
40 Jalanka J, Mattila E, Jouhten H, Hartman J, de Vos WM, Arkkila P, Satokari R. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med. 2016;14:155. [PMID: 27724956 DOI: 10.1186/s12916-016-0698-z] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 10.5] [Reference Citation Analysis]
41 Gao X, Wang X, Pham TH, Feuerbacher LA, Lubos ML, Huang M, Olsen R, Mushegian A, Slawson C, Hardwidge PR. NleB, a bacterial effector with glycosyltransferase activity, targets GAPDH function to inhibit NF-κB activation. Cell Host Microbe 2013;13:87-99. [PMID: 23332158 DOI: 10.1016/j.chom.2012.11.010] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 10.8] [Reference Citation Analysis]
42 Brown KA, Fisman DN, Moineddin R, Daneman N. The magnitude and duration of Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort study. PLoS One 2014;9:e105454. [PMID: 25157757 DOI: 10.1371/journal.pone.0105454] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
43 Li S, Shi L, Yang Z, Feng H. Cytotoxicity of Clostridium difficile toxin B does not require cysteine protease-mediated autocleavage and release of the glucosyltransferase domain into the host cell cytosol. Pathog Dis 2013;67:11-8. [PMID: 23620115 DOI: 10.1111/2049-632X.12016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
44 Motzkus-Feagans CA, Pakyz A, Polk R, Gambassi G, Lapane KL. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 2012;61:1538-42. [PMID: 22442166 DOI: 10.1136/gutjnl-2011-301378] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
45 Swick MC, Koehler TM, Driks A. Surviving Between Hosts: Sporulation and Transmission. Microbiol Spectr 2016;4. [PMID: 27726794 DOI: 10.1128/microbiolspec.VMBF-0029-2015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
46 Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe. 2011;10:311-323. [PMID: 22018232 DOI: 10.1016/j.chom.2011.10.004] [Cited by in Crossref: 313] [Cited by in F6Publishing: 291] [Article Influence: 31.3] [Reference Citation Analysis]
47 Pakpour S, Bhanvadia A, Zhu R, Amarnani A, Gibbons SM, Gurry T, Alm EJ, Martello LA. Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment. Microbiome 2017;5:148. [PMID: 29132405 DOI: 10.1186/s40168-017-0368-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
48 Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, Pardi DS. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1466-1471. [PMID: 23702192 DOI: 10.1016/j.cgh.2013.04.050] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
49 Ting LS, Praestgaard J, Grunenberg N, Yang JC, Leeds JA, Pertel P. A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers. Antimicrob Agents Chemother 2012;56:5946-51. [PMID: 22964250 DOI: 10.1128/AAC.00867-12] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
50 DeNegre AA, Ndeffo Mbah ML, Myers K, Fefferman NH. Emergence of antibiotic resistance in immunocompromised host populations: A case study of emerging antibiotic resistant tuberculosis in AIDS patients. PLoS One 2019;14:e0212969. [PMID: 30817798 DOI: 10.1371/journal.pone.0212969] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
51 Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur J Clin Microbiol Infect Dis 2012;31:3163-71. [PMID: 22752150 DOI: 10.1007/s10096-012-1681-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
52 Shayganmehr FS, Alebouyeh M, Azimirad M, Aslani MM, Zali MR. Association of tcdA+/tcdB+ Clostridium difficile Genotype with Emergence of Multidrug-Resistant Strains Conferring Metronidazole Resistant Phenotype. Iran Biomed J 2015;19:143-8. [PMID: 26048022 DOI: 10.7508/ibj.2015.03.003] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
53 Lee BY, Popovich MJ, Tian Y, Bailey RR, Ufberg PJ, Wiringa AE, Muder RR. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010;28:5245-53. [PMID: 20541582 DOI: 10.1016/j.vaccine.2010.05.062] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
54 Zhang Y, Feng H. Pathogenic effects of glucosyltransferase from Clostridium difficile toxins. Pathog Dis 2016;74:ftw024. [PMID: 27044305 DOI: 10.1093/femspd/ftw024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 He X, Wang J, Steele J, Sun X, Nie W, Tzipori S, Feng H. An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods 2009;78:97-100. [PMID: 19393695 DOI: 10.1016/j.mimet.2009.04.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
56 Wang S, Wang Y, Cai Y, Kelly CP, Sun X. Novel Chimeric Protein Vaccines Against Clostridium difficile Infection. Front Immunol 2018;9:2440. [PMID: 30405630 DOI: 10.3389/fimmu.2018.02440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
57 Boix V, Fedorak RN, Mullane KM, Pesant Y, Stoutenburgh U, Jin M, Adedoyin A, Chesnel L, Guris D, Larson KB, Murata Y. Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection. Open Forum Infect Dis 2017;4:ofw275. [PMID: 28480267 DOI: 10.1093/ofid/ofw275] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
58 Codella J, Safdar N, Heffernan R, Alagoz O. An agent-based simulation model for Clostridium difficile infection control. Med Decis Making 2015;35:211-29. [PMID: 25112595 DOI: 10.1177/0272989X14545788] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
59 Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization With Toxinogenic C. difficile Upon Hospital Admission, and Risk of Infection: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2015;110:381-90. [DOI: 10.1038/ajg.2015.22] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 18.1] [Reference Citation Analysis]
60 Cecil JA. Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures. Curr Infect Dis Rep. 2012;14:612-619. [PMID: 23054932 DOI: 10.1007/s11908-012-0298-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
61 Cole SA, Stahl TJ. Persistent and Recurrent Clostridium difficile Colitis. Clin Colon Rectal Surg 2015;28:65-9. [PMID: 26034401 DOI: 10.1055/s-0035-1547333] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
62 Chia JH, Lai HC, Su LH, Kuo AJ, Wu TL. Molecular epidemiology of Clostridium difficile at a medical center in Taiwan: persistence of genetically clustering of A⁻B⁺ isolates and increase of A⁺B⁺ isolates. PLoS One 2013;8:e75471. [PMID: 24116048 DOI: 10.1371/journal.pone.0075471] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
63 Carvalho P, Barbosa J, Teixeira P. Are meats indeed sold in Portugal without Clostridioides difficile?. Acta Alimentaria 2019;48:391-5. [DOI: 10.1556/066.2019.48.3.15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Zhang Z, Park M, Tam J, Auger A, Beilhartz GL, Lacy DB, Melnyk RA. Translocation domain mutations affecting cellular toxicity identify the Clostridium difficile toxin B pore. Proc Natl Acad Sci U S A 2014;111:3721-6. [PMID: 24567384 DOI: 10.1073/pnas.1400680111] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
65 Mavros MN, Alexiou VG, Vardakas KZ, Tsokali K, Sardi TA, Falagas ME. Underestimation of Clostridium difficile infection among clinicians: an international survey. Eur J Clin Microbiol Infect Dis 2012;31:2439-44. [PMID: 22450740 DOI: 10.1007/s10096-012-1587-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
66 Almeida R, Gerbaba T, Petrof EO. Recurrent Clostridium difficile infection and the microbiome. J Gastroenterol 2016;51:1-10. [PMID: 26153514 DOI: 10.1007/s00535-015-1099-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
67 Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P, Fang FC, Dascal A, Gerding DN, Nomura JH. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol. 2010;48:3719-3724. [PMID: 20702676 DOI: 10.1128/jcm.00427-10] [Cited by in Crossref: 162] [Cited by in F6Publishing: 68] [Article Influence: 13.5] [Reference Citation Analysis]
68 Dubberke ER, Reske KA, Seiler S, Hink T, Kwon JH, Burnham CA. Risk Factors for Acquisition and Loss of Clostridium difficile Colonization in Hospitalized Patients. Antimicrob Agents Chemother 2015;59:4533-43. [PMID: 25987626 DOI: 10.1128/AAC.00642-15] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
69 Rohana H, Azrad M, Nitzan O, Adler A, Binyamin D, Koren O, Peretz A. Characterization of Clostridioides difficile Strains, the Disease Severity, and the Microbial Changes They Induce. J Clin Med 2020;9:E4099. [PMID: 33353133 DOI: 10.3390/jcm9124099] [Reference Citation Analysis]
70 Barbut F, Monot M, Rousseau A, Cavelot S, Simon T, Burghoffer B, Lalande V, Tankovic J, Petit JC, Dupuy B. Rapid diagnosis of Clostridium difficile infection by multiplex real-time PCR. Eur J Clin Microbiol Infect Dis. 2011;30:1279-1285. [PMID: 21487764 DOI: 10.1007/s10096-011-1224-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
71 Carmo J, Marques S, Chapim I, Túlio MA, Rodrigues JP, Bispo M, Chagas C. Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015. GE Port J Gastroenterol 2015;22:259-67. [PMID: 28868417 DOI: 10.1016/j.jpge.2015.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
72 Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55 Suppl 2:S132-S142. [PMID: 22752862 DOI: 10.1093/cid/cis338] [Cited by in Crossref: 186] [Cited by in F6Publishing: 164] [Article Influence: 18.6] [Reference Citation Analysis]
73 Lakes JE, Richards CI, Flythe MD. Inhibition of Bacteroidetes and Firmicutes by select phytochemicals. Anaerobe 2020;61:102145. [PMID: 31918362 DOI: 10.1016/j.anaerobe.2019.102145] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
74 Garey KW, Aitken SL, Gschwind L, Goddu S, Xie Y, Duff C, Barbut F, Shah DN, DuPont HL. Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol 2016;50:631-7. [PMID: 26796081 DOI: 10.1097/MCG.0000000000000473] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 4.2] [Reference Citation Analysis]
75 Goudarzi M, Goudarzi H, Alebouyeh M, Azimi Rad M, Shayegan Mehr FS, Zali MR, Aslani MM. Antimicrobial susceptibility of clostridium difficile clinical isolates in iran. Iran Red Crescent Med J 2013;15:704-11. [PMID: 24578839 DOI: 10.5812/ircmj.5189] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
76 Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107:89-95. [PMID: 22108454 DOI: 10.1038/ajg.2011.398] [Cited by in Crossref: 395] [Cited by in F6Publishing: 362] [Article Influence: 35.9] [Reference Citation Analysis]
77 Dylewski J. The value of repeat Clostridium difficile toxin testing during and after an outbreak of C difficile-associated diarrhea. Can J Infect Dis Med Microbiol 2011;22:e12-5. [PMID: 22654928 DOI: 10.1155/2011/591239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
78 Taniguchi H, Tanisawa K, Sun X, Kubo T, Hoshino Y, Hosokawa M, Takeyama H, Higuchi M. Effects of short-term endurance exercise on gut microbiota in elderly men. Physiol Rep. 2018;6:e13935. [PMID: 30536648 DOI: 10.14814/phy2.13935] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
79 Zhu Z, Schnell L, Müller B, Müller M, Papatheodorou P, Barth H. The Antibiotic Bacitracin Protects Human Intestinal Epithelial Cells and Stem Cell-Derived Intestinal Organoids from Clostridium difficile Toxin TcdB. Stem Cells Int 2019;2019:4149762. [PMID: 31467562 DOI: 10.1155/2019/4149762] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
80 Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP. Recurrent Clostridium difficile infection: From colonization to cure. Anaerobe 2015;34:59-73. [PMID: 25930686 DOI: 10.1016/j.anaerobe.2015.04.012] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 7.7] [Reference Citation Analysis]
81 Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, Maschmeyer G, Schalk E, Vehreschild JJ, Vehreschild MJGT; AGIHO Working Group. Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2018;97:31-49. [PMID: 29177551 DOI: 10.1007/s00277-017-3183-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
82 Huang H, Weintraub A, Fang H, Nord CE. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections. J Clin Microbiol. 2009;47:3729-3731. [PMID: 19741082 DOI: 10.1128/jcm.01280-09] [Cited by in Crossref: 71] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
83 Mitchell BG, Gardner A. Mortality and Clostridium difficile infection: a review. Antimicrob Resist Infect Control 2012;1:20. [PMID: 22958425 DOI: 10.1186/2047-2994-1-20] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
84 Vital M, Gao J, Rizzo M, Harrison T, Tiedje JM. Diet is a major factor governing the fecal butyrate-producing community structure across Mammalia, Aves and Reptilia. ISME J 2015;9:832-43. [PMID: 25343515 DOI: 10.1038/ismej.2014.179] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 8.7] [Reference Citation Analysis]
85 Deakin LJ, Clare S, Fagan RP, Dawson LF, Pickard DJ, West MR, Wren BW, Fairweather NF, Dougan G, Lawley TD. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun. 2012;80:2704-2711. [PMID: 22615253 DOI: 10.1128/iai.00147-12] [Cited by in Crossref: 229] [Cited by in F6Publishing: 160] [Article Influence: 22.9] [Reference Citation Analysis]
86 Orenstein R, Patron RL. Clostridioides difficile therapeutics: guidelines and beyond. Ther Adv Infect Dis 2019;6:2049936119868548. [PMID: 31448117 DOI: 10.1177/2049936119868548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
87 Amadou Amani S, Shadid T, Ballard JD, Lang ML. Clostridioides difficile Infection Induces an Inferior IgG Response to That Induced by Immunization and Is Associated with a Lack of T Follicular Helper Cell and Memory B Cell Expansion. Infect Immun 2020;88:e00829-19. [PMID: 31871095 DOI: 10.1128/IAI.00829-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Corbett D, Wise A, Birchall S, Warn P, Baines SD, Crowther G, Freeman J, Chilton CH, Vernon J, Wilcox MH, Vickers RJ. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. J Antimicrob Chemother 2015;70:1751-6. [PMID: 25652750 DOI: 10.1093/jac/dkv006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
89 Mihajlov K, Andreska A, Ristovska N, Grdanoska T, Trajkovska-Dokic E. Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility. Open Access Maced J Med Sci 2019;7:1896-9. [PMID: 31406525 DOI: 10.3889/oamjms.2019.482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107:89-95. [PMID: 22108454 DOI: 10.1038/ajg.2011.398ajg2011398] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Meehan AM, Tariq R, Khanna S. Challenges in management of recurrent and refractory Clostridium difficile infection. World J Clin Infect Dis 2016; 6(3): 28-36 [DOI: 10.5495/wjcid.v6.i3.28] [Reference Citation Analysis]
92 Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55 Suppl 2:S65-S70. [PMID: 22752867 DOI: 10.1093/cid/cis319] [Cited by in Crossref: 281] [Cited by in F6Publishing: 249] [Article Influence: 28.1] [Reference Citation Analysis]
93 Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes. 2011;2:145-158. [PMID: 21804357 DOI: 10.4161/gmic.2.3.16333] [Cited by in Crossref: 185] [Cited by in F6Publishing: 173] [Article Influence: 16.8] [Reference Citation Analysis]
94 Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P, Raisen C, Mottram L. Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun. 2009;77:3661-3669. [PMID: 19564382 DOI: 10.1128/iai.00558-09] [Cited by in Crossref: 251] [Cited by in F6Publishing: 181] [Article Influence: 19.3] [Reference Citation Analysis]
95 Tsutsumi LS, Owusu YB, Hurdle JG, Sun D. Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem 2014;14:152-75. [PMID: 24236721 DOI: 10.2174/1568026613666131113154753] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
96 Vincent C, Mehrotra S, Loo VG, Dewar K, Manges AR. Excretion of Host DNA in Feces Is Associated with Risk of Clostridium difficile Infection. J Immunol Res 2015;2015:246203. [PMID: 26090486 DOI: 10.1155/2015/246203] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
97 Johnson TM, Howard AH, Miller MA, Allen LL, Huang M, Molina KC, Bajrovic V. Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients. Open Forum Infect Dis 2021;8:ofab294. [PMID: 34262988 DOI: 10.1093/ofid/ofab294] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Ianiro G, Bibbò S, Scaldaferri F, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore) 2014;93:e97. [PMID: 25340496 DOI: 10.1097/MD.0000000000000097] [Cited by in Crossref: 54] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
99 Hernandez BG, Vinithakumari AA, Sponseller B, Tangudu C, Mooyottu S. Prevalence, Colonization, Epidemiology, and Public Health Significance of Clostridioides difficile in Companion Animals. Front Vet Sci 2020;7:512551. [PMID: 33062657 DOI: 10.3389/fvets.2020.512551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ 2019;7:e7502. [PMID: 31440436 DOI: 10.7717/peerj.7502] [Cited by in Crossref: 95] [Cited by in F6Publishing: 77] [Article Influence: 31.7] [Reference Citation Analysis]
101 Aguilar RC, Salmanton-García J, Carney J, Böll B, Kochanek M, Jazmati N, Cornely OA, Vehreschild MJGT. Clostridioides difficile infections in the intensive care unit: a monocentric cohort study. Infection 2020;48:421-7. [PMID: 32212102 DOI: 10.1007/s15010-020-01413-8] [Reference Citation Analysis]
102 Bassères E, Endres BT, Khaleduzzaman M, Miraftabi F, Alam MJ, Vickers RJ, Garey KW. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother 2016;71:1245-51. [PMID: 26895772 DOI: 10.1093/jac/dkv498] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
103 Garg S, Mirza YR, Girotra M, Kumar V, Yoselevitz S, Segon A, Dutta SK. Epidemiology of Clostridium difficile-associated disease (CDAD): a shift from hospital-acquired infection to long-term care facility-based infection. Dig Dis Sci. 2013;58:3407-3412. [PMID: 24154638 DOI: 10.1007/s10620-013-2848-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
104 Saha S, Khanna S. Microbiota replacement for Clostridium difficile by capsule is as effective as via colonoscopy. J Thorac Dis. 2018;10:S1081-S1083. [PMID: 29849203 DOI: 10.21037/jtd.2018.04.18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
105 Li Y, Huang Y, Li Y, Nie Y. Clinical characteristics of Clostridium difficile-associated diarrhea among patients in a tertiary care center in China. Pak J Med Sci 2016;32:736-41. [PMID: 27375724 DOI: 10.12669/pjms.323.9400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
106 Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016;11:e0161174. [PMID: 27529553 DOI: 10.1371/journal.pone.0161174] [Cited by in Crossref: 163] [Cited by in F6Publishing: 145] [Article Influence: 27.2] [Reference Citation Analysis]
107 Staley C, Kaiser T, Vaughn BP, Graiziger CT, Hamilton MJ, Rehman TU, Song K, Khoruts A, Sadowsky MJ. Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation. Microbiome 2018;6:166. [PMID: 30227892 DOI: 10.1186/s40168-018-0549-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
108 Cristina ML, Spagnolo AM, Sartini M, Panatto D, Perdelli F. Clostridium difficile infections: an emerging problem in healthcare facilities. Reviews in Medical Microbiology 2012;23:67-75. [DOI: 10.1097/mrm.0b013e3283573643] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
109 Geiger TL, Abt MC, Gasteiger G, Firth MA, O'Connor MH, Geary CD, O'Sullivan TE, van den Brink MR, Pamer EG, Hanash AM, Sun JC. Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens. J Exp Med 2014;211:1723-31. [PMID: 25113970 DOI: 10.1084/jem.20140212] [Cited by in Crossref: 174] [Cited by in F6Publishing: 162] [Article Influence: 21.8] [Reference Citation Analysis]
110 Nathanson BH, Higgins TL, McGee WT. The dangers of extreme body mass index values in patients with Clostridium difficile. Infection 2017;45:787-93. [PMID: 28593617 DOI: 10.1007/s15010-017-1036-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
111 Tousseeva A, Jackson JD, Redell M, Henry T, Hui M, Capurso S, DeRyke CA. Stability and recovery of DIFICID(®) (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube. Drugs R D 2014;14:309-14. [PMID: 25424419 DOI: 10.1007/s40268-014-0067-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
112 Ross CL, Spinler JK, Savidge TC. Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection. Anaerobe 2016;41:37-43. [PMID: 27180006 DOI: 10.1016/j.anaerobe.2016.05.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
113 Winston JA, Thanissery R, Montgomery SA, Theriot CM. Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291. J Vis Exp 2016. [PMID: 28060346 DOI: 10.3791/54850] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
114 Banawas SS. Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms. Biomed Res Int 2018;2018:8414257. [PMID: 29682562 DOI: 10.1155/2018/8414257] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
115 Lee CH, Belanger JE, Kassam Z, Smieja M, Higgins D, Broukhanski G, Kim PT. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis. 2014;33:1425-1428. [PMID: 24627239 DOI: 10.1007/s10096-014-2088-9] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 9.6] [Reference Citation Analysis]
116 Shah DN, Chan FS, Kachru N, Garcia KP, Balcer HE, Dyer AP, Emanuel JE, Jordan MD, Lusardi KT, Naymick G, Polisetty RS, Sieman L, Tyler AM, Johnson ML, Garey KW. A multi-center study of fidaxomicin use for Clostridium difficile infection. Springerplus 2016;5:1224. [PMID: 27536508 DOI: 10.1186/s40064-016-2825-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
117 Álvarez-Hernández DA, González-Chávez AM, González-Hermosillo-Cornejo D, Franyuti-Kelly GA, Díaz-Girón-Gidi A, Vázquez-López R. Present and past perspectives on Clostridium difficile infection. Rev Gastroenterol Mex (Engl Ed) 2018;83:41-50. [PMID: 28684034 DOI: 10.1016/j.rgmx.2017.03.004] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
118 Di Bella S, Paglia MG, Johnson E, Petrosillo N. Clostridium difficile 027 infection in Central Italy. BMC Infect Dis 2012;12:370. [PMID: 23259814 DOI: 10.1186/1471-2334-12-370] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
119 Arimoto J, Horita N, Kato S, Fuyuki A, Higurashi T, Ohkubo H, Endo H, Takashi N, Kaneko T, Nakajima A. Diagnostic test accuracy of glutamate dehydrogenase for Clostridium difficile: Systematic review and meta-analysis. Sci Rep 2016;6:29754. [PMID: 27418431 DOI: 10.1038/srep29754] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
120 Goldenberg SD, Brown S, Edwards L, Gnanarajah D, Howard P, Jenkins D, Nayar D, Pasztor M, Oliver S, Planche T, Sandoe JA, Wade P, Whitney L. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis 2016;35:251-9. [PMID: 26661400 DOI: 10.1007/s10096-015-2538-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
121 Malnick S, Melzer E. Human microbiome: From the bathroom to the bedside. World J Gastrointest Pathophysiol 2015; 6(3): 79-85 [PMID: 26301122 DOI: 10.4291/wjgp.v6.i3.79] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
122 Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection. Can J Gastroenterol Hepatol 2014;28:319-24. [PMID: 24719899 DOI: 10.1155/2014/403828] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
123 Jarchum I, Liu M, Lipuma L, Pamer EG. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun 2011;79:1498-503. [PMID: 21245274 DOI: 10.1128/IAI.01196-10] [Cited by in Crossref: 102] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
124 Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 2013;4:125-35. [PMID: 23333862 DOI: 10.4161/gmic.23571] [Cited by in Crossref: 206] [Cited by in F6Publishing: 190] [Article Influence: 22.9] [Reference Citation Analysis]
125 Halvorson SA, Cedfeldt AS, Hunter AJ. Fulminant, non-antibiotic associated Clostridium difficile colitis following Salmonella gastroenteritis. J Gen Intern Med 2011;26:95-7. [PMID: 20697966 DOI: 10.1007/s11606-010-1466-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
126 Scaria J, Suzuki H, Ptak CP, Chen JW, Zhu Y, Guo XK, Chang YF. Comparative genomic and phenomic analysis of Clostridium difficile and Clostridium sordellii, two related pathogens with differing host tissue preference. BMC Genomics 2015;16:448. [PMID: 26059449 DOI: 10.1186/s12864-015-1663-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
127 Schwan C, Nölke T, Kruppke AS, Schubert DM, Lang AE, Aktories K. Cholesterol- and sphingolipid-rich microdomains are essential for microtubule-based membrane protrusions induced by Clostridium difficile transferase (CDT). J Biol Chem 2011;286:29356-65. [PMID: 21705797 DOI: 10.1074/jbc.M111.261925] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
128 Weingarden AR, Dosa PI, DeWinter E, Steer CJ, Shaughnessy MK, Johnson JR, Khoruts A, Sadowsky MJ. Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. PLoS One 2016;11:e0147210. [PMID: 26789728 DOI: 10.1371/journal.pone.0147210] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 13.5] [Reference Citation Analysis]
129 Vincent C, Miller MA, Edens TJ, Mehrotra S, Dewar K, Manges AR. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome 2016;4:12. [PMID: 26975510 DOI: 10.1186/s40168-016-0156-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 10.3] [Reference Citation Analysis]
130 Hooker EA, Bochan M, Reiff TT, Blackwell C, Webb KW, Hart KW. Decreasing Clostridium difficile health care-associated infections through use of a launderable mattress cover. Am J Infect Control 2015;43:1326-30. [PMID: 26498703 DOI: 10.1016/j.ajic.2015.07.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
131 Dickinson B, Surawicz CM. Infectious diarrhea: an overview. Curr Gastroenterol Rep. 2014;16:399. [PMID: 25064318 DOI: 10.1007/s11894-014-0399-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
132 Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011;9:88-96. [PMID: 22183182 DOI: 10.1038/nrgastro.2011.244] [Cited by in Crossref: 367] [Cited by in F6Publishing: 333] [Article Influence: 33.4] [Reference Citation Analysis]
133 Steinebrunner N, Stremmel W, Weiss KH. Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection. J Thorac Dis 2018;10:118-20. [PMID: 29600036 DOI: 10.21037/jtd.2017.12.117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
134 Drozd EM, Inocencio TJ, Braithwaite S, Jagun D, Shah H, Quon NC, Broderick KC, Kuti JL. Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection Among Medicare Beneficiaries. Infect Dis Clin Pract (Baltim Md) 2015;23:318-23. [PMID: 27885315 DOI: 10.1097/IPC.0000000000000299] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
135 Ridha A, Safiullah SM, Al-Abayechi S, Nadeem AUR. Acute Appendicitis: An Extracolonic Manifestation of Clostridium difficile Colitis. Case Rep Med 2017;2017:5083535. [PMID: 28757875 DOI: 10.1155/2017/5083535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
136 Li D, Ren AM. Treatment of Clostridium difficile-associated diarrhea. Shijie Huaren Xiaohua Zazhi 2012; 20(6): 497-504 [DOI: 10.11569/wcjd.v20.i6.497] [Reference Citation Analysis]
137 Rafiullah F, Kanwal S, Majeed UM, Korsten MA, Cheema FH, Luthra M, Sohail MR. Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection. BMJ Case Rep 2011;2011:bcr0420114123. [PMID: 22674696 DOI: 10.1136/bcr.04.2011.4123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
138 Kumar A, Ghazanfar H, Davidson JM. A Rare Case of Arterial and Venous Thromboembolism in a Patient With Severe Clostridium difficile Infection. Cureus 2021;13:e16103. [PMID: 34258130 DOI: 10.7759/cureus.16103] [Reference Citation Analysis]
139 Khanna S, Pardi DS, Aronson SL, Kammer PP, Baddour LM. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther. 2012;35:613-618. [PMID: 22229532 DOI: 10.1111/j.1365-2036.2011.04984.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
140 Nerandzic MM, Rackaityte E, Jury LA, Eckart K, Donskey CJ. Novel strategies for enhanced removal of persistent Bacillus anthracis surrogates and Clostridium difficile spores from skin. PLoS One 2013;8:e68706. [PMID: 23844234 DOI: 10.1371/journal.pone.0068706] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
141 Shen A. Allosteric regulation of protease activity by small molecules. Mol Biosyst 2010;6:1431-43. [PMID: 20539873 DOI: 10.1039/c003913f] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
142 Zhu S, Zhang L, Zhang C, Chen X, Chen Q, Li Z. Comparison of polymerase chain reaction ribotyping, toxinotyping and nutritional aspects of toxin production of Clostridium difficile strains. Biomed Rep 2014;2:477-80. [PMID: 24944791 DOI: 10.3892/br.2014.270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
143 Aletaha N, Dadvar Z, Salehi B, Ketabi Moghadam P, Niksirat A, Jowkar A, Taslimi R, Allameh SF, Ebrahimi Daryani N. Clinical and Pathological Features of Ulcerative Colitis in Patients with and without Clostridium Difficile Infection; An Observational Study. Middle East J Dig Dis 2019;11:17-23. [PMID: 31049178 DOI: 10.15171/mejdd.2018.123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
144 Oleastro M, Coelho M, Gião M, Coutinho S, Mota S, Santos A, Rodrigues J, Faria D. Outbreak of Clostridium difficile PCR ribotype 027--the recent experience of a regional hospital. BMC Infect Dis 2014;14:209. [PMID: 24739945 DOI: 10.1186/1471-2334-14-209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
145 Na X, Martin AJ, Sethi S, Kyne L, Garey KW, Flores SW, Hu M, Shah DN, Shields K, Leffler DA, Kelly CP. A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. PLoS One 2015;10:e0123405. [PMID: 25906284 DOI: 10.1371/journal.pone.0123405] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
146 Gribenko A, Severina E, Sidhu MK, Jansen KU, Green BA, Matsuka YV. Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B. Biochem Biophys Rep 2017;9:193-202. [PMID: 28956005 DOI: 10.1016/j.bbrep.2016.12.015] [Reference Citation Analysis]
147 Farrow MA, Chumbler NM, Lapierre LA, Franklin JL, Rutherford SA, Goldenring JR, Lacy DB. Clostridium difficile toxin B-induced necrosis is mediated by the host epithelial cell NADPH oxidase complex. Proc Natl Acad Sci U S A 2013;110:18674-9. [PMID: 24167244 DOI: 10.1073/pnas.1313658110] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 9.2] [Reference Citation Analysis]
148 Lin YC, Huang YT, Tsai PJ, Lee TF, Lee NY, Liao CH, Lin SY, Ko WC, Hsueh PR. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan. Antimicrob Agents Chemother 2011;55:1701-5. [PMID: 21263053 DOI: 10.1128/AAC.01440-10] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
149 Gouliouris T, Brown NM, Aliyu SH. Prevention and treatment of Clostridium difficile infection. Clin Med (Lond) 2011;11:75-9. [PMID: 21404793 DOI: 10.7861/clinmedicine.11-1-75] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
150 Hai Z, Peng Zhen L, Juan M, Fan Y, Jin Rong C, Jing Yao L, Li Xia Z. Extraintestinal Clostridioides difficile infection. IDCases 2020;22:e00921. [PMID: 32923365 DOI: 10.1016/j.idcr.2020.e00921] [Reference Citation Analysis]
151 Schorch B, Song S, van Diemen FR, Bock HH, May P, Herz J, Brummelkamp TR, Papatheodorou P, Aktories K. LRP1 is a receptor for Clostridium perfringens TpeL toxin indicating a two-receptor model of clostridial glycosylating toxins. Proc Natl Acad Sci U S A 2014;111:6431-6. [PMID: 24737893 DOI: 10.1073/pnas.1323790111] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 7.6] [Reference Citation Analysis]
152 Antoon JW, Hall M, Metropulos D, Steiner MJ, Jhaveri R, Lohr JA. A Prospective Pilot Study on the Systemic Absorption of Oral Vancomycin in Children With Colitis. J Pediatr Pharmacol Ther 2016;21:426-31. [PMID: 27877096 DOI: 10.5863/1551-6776-21.5.426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
153 Vincent C, Manges AR. Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection. Antibiotics (Basel) 2015;4:230-53. [PMID: 27025623 DOI: 10.3390/antibiotics4030230] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
154 Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc. 2012;87:636-642. [PMID: 22766083 DOI: 10.1016/j.mayocp.2011.12.021] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
155 Etienne-Mesmin L, Chassaing B, Adekunle O, Mattei LM, Edwards AN, McBride SM, Bushman FD, Gewirtz AT. Genome Sequence of a Toxin-Positive Clostridium difficile Strain Isolated from Murine Feces. Genome Announc 2017;5:e00088-17. [PMID: 28385835 DOI: 10.1128/genomeA.00088-17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
156 Ghose C, Eugenis I, Edwards AN, Sun X, McBride SM, Ho DD. Immunogenicity and protective efficacy of Clostridium difficile spore proteins. Anaerobe 2016;37:85-95. [PMID: 26688279 DOI: 10.1016/j.anaerobe.2015.12.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
157 Chandrasekaran R, Kenworthy AK, Lacy DB. Clostridium difficile Toxin A Undergoes Clathrin-Independent, PACSIN2-Dependent Endocytosis. PLoS Pathog 2016;12:e1006070. [PMID: 27942025 DOI: 10.1371/journal.ppat.1006070] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
158 Arthithanyaroj S, Chankhamhaengdecha S, Chaisri U, Aunpad R, Aroonnual A. Effective inhibition of Clostridioides difficile by the novel peptide CM-A. PLoS One 2021;16:e0257431. [PMID: 34516580 DOI: 10.1371/journal.pone.0257431] [Reference Citation Analysis]
159 Khanna S, Gupta A, Baddour LM, Pardi DS. Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection. Intern Emerg Med 2016;11:657-65. [PMID: 26694494 DOI: 10.1007/s11739-015-1366-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
160 Song L, Zhao M, Duffy DC, Hansen J, Shields K, Wungjiranirun M, Chen X, Xu H, Leffler DA, Sambol SP, Gerding DN, Kelly CP, Pollock NR. Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool. J Clin Microbiol 2015;53:3204-12. [PMID: 26202120 DOI: 10.1128/JCM.01334-15] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 4.9] [Reference Citation Analysis]
161 Butler MM, Shinabarger DL, Citron DM, Kelly CP, Dvoskin S, Wright GE, Feng H, Tzipori S, Bowlin TL. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother 2012;56:4786-92. [PMID: 22733075 DOI: 10.1128/AAC.00508-12] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
162 Dumic I, Nordin T, Jecmenica M, Stojkovic Lalosevic M, Milosavljevic T, Milovanovic T. Gastrointestinal Tract Disorders in Older Age. Can J Gastroenterol Hepatol 2019;2019:6757524. [PMID: 30792972 DOI: 10.1155/2019/6757524] [Cited by in Crossref: 51] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
163 Karadsheh Z, Sule S. Fecal transplantation for the treatment of recurrent clostridium difficile infection. N Am J Med Sci. 2013;5:339-343. [PMID: 23923106 DOI: 10.4103/1947-2714.114163] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
164 Kaltsas A, Simon M, Unruh LH, Son C, Wroblewski D, Musser KA, Sepkowitz K, Babady NE, Kamboj M. Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test results. J Clin Microbiol 2012;50:1303-7. [PMID: 22238444 DOI: 10.1128/JCM.05711-11] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
165 Hamza T, Zhang Z, Melnyk RA, Feng H. Defective mutations within the translocation domain of Clostridium difficile toxin B impair disease pathogenesis. Pathog Dis 2016;74:ftv098. [PMID: 26507679 DOI: 10.1093/femspd/ftv098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
166 Hui W, Li T, Liu W, Zhou C, Gao F. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis. PLoS One. 2019;14:e0210016. [PMID: 30673716 DOI: 10.1371/journal.pone.0210016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 15.7] [Reference Citation Analysis]
167 Chen S, Wang H, Gu H, Sun C, Li S, Feng H, Wang J. Identification of an Essential Region for Translocation of Clostridium difficile Toxin B. Toxins (Basel) 2016;8:E241. [PMID: 27537911 DOI: 10.3390/toxins8080241] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
168 Kim GH, Kim J, Pai H, Kang JO. Comparison of supplemented Brucella agar and modified Clostridium difficile agar for antimicrobial susceptibility testing of Clostridium difficile. Ann Lab Med 2014;34:439-45. [PMID: 25368819 DOI: 10.3343/alm.2014.34.6.439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Asempa TE, Nicolau DP. Clostridium difficile infection in the elderly: an update on management. Clin Interv Aging 2017;12:1799-809. [PMID: 29123385 DOI: 10.2147/CIA.S149089] [Cited by in Crossref: 38] [Cited by in F6Publishing: 18] [Article Influence: 7.6] [Reference Citation Analysis]
170 Kim H, Kim WH, Kim M, Jeong SH, Lee K. Evaluation of a rapid membrane enzyme immunoassay for the simultaneous detection of glutamate dehydrogenase and toxin for the diagnosis of Clostridium difficile infection. Ann Lab Med. 2014;34:235-239. [PMID: 24790912 DOI: 10.3343/alm.2014.34.3.235] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
171 Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc 2011;86:1113-23. [PMID: 22033257 DOI: 10.4065/mcp.2011.0358] [Cited by in Crossref: 175] [Cited by in F6Publishing: 148] [Article Influence: 15.9] [Reference Citation Analysis]
172 Nakao S, Hasegawa S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Uranishi H, Masuta M, Ikesue H, Hashida T, Iguchi K, Nakamura M. Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. Int J Med Sci 2020;17:921-30. [PMID: 32308545 DOI: 10.7150/ijms.43789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
173 Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis 2012;55:615-20. [PMID: 22563022 DOI: 10.1093/cid/cis457] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
174 Khanna S, Baddour LM, Huskins WC, Kammer PP, Faubion WA, Zinsmeister AR, Harmsen WS, Pardi DS. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013;56:1401-1406. [PMID: 23408679 DOI: 10.1093/cid/cit075] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 15.6] [Reference Citation Analysis]
175 Ransom EM, Williams KB, Weiss DS, Ellermeier CD. Identification and characterization of a gene cluster required for proper rod shape, cell division, and pathogenesis in Clostridium difficile. J Bacteriol 2014;196:2290-300. [PMID: 24727226 DOI: 10.1128/JB.00038-14] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
176 Lewis SS, Anderson DJ. Treatment of Clostridium difficile infection: recent trial results. Clin Investig (Lond) 2013;3:875-86. [PMID: 25525499 DOI: 10.4155/cli.13.72] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
177 Pruitt RN, Lacy DB. Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol 2012;2:28. [PMID: 22919620 DOI: 10.3389/fcimb.2012.00028] [Cited by in Crossref: 109] [Cited by in F6Publishing: 91] [Article Influence: 10.9] [Reference Citation Analysis]
178 Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, Alm EJ, Gevers D, Russell GH, Hohmann EL. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58:1515-1522. [PMID: 24762631 DOI: 10.1093/cid/ciu135] [Cited by in Crossref: 295] [Cited by in F6Publishing: 243] [Article Influence: 36.9] [Reference Citation Analysis]
179 Yang Z, Ramsey J, Hamza T, Zhang Y, Li S, Yfantis HG, Lee D, Hernandez LD, Seghezzi W, Furneisen JM, Davis NM, Therien AG, Feng H. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun 2015;83:822-31. [PMID: 25486992 DOI: 10.1128/IAI.02897-14] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 7.9] [Reference Citation Analysis]
180 Chumbler NM, Farrow MA, Lapierre LA, Franklin JL, Lacy DB. Clostridium difficile Toxins TcdA and TcdB Cause Colonic Tissue Damage by Distinct Mechanisms. Infect Immun 2016;84:2871-7. [PMID: 27456833 DOI: 10.1128/IAI.00583-16] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
181 Meng X, Huang X, Peng Z, Wang Y, Liu S, Zeng C, Duan J, Wen X, Fu C, Wu A, Li C. Antibiotic Resistances and Molecular Characteristics of Clostridioides difficile in ICUs in a Teaching Hospital From Central South China. Front Med (Lausanne) 2021;8:745383. [PMID: 34938744 DOI: 10.3389/fmed.2021.745383] [Reference Citation Analysis]
182 Chen Y, Zhao Y, Cheng Q, Wu D, Liu H. The Role of Intestinal Microbiota in Acute Graft-versus-Host Disease. J Immunol Res 2015;2015:145859. [PMID: 26090477 DOI: 10.1155/2015/145859] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
183 Hopkins CJ. Inpatient antibiotic consumption in a regional secondary hospital in New Zealand. Intern Med J 2014;44:185-90. [PMID: 24528814 DOI: 10.1111/imj.12345] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries. J Am Coll Surg 2014;218:1141-1147.e1. [PMID: 24755188 DOI: 10.1016/j.jamcollsurg.2014.01.053] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
185 Xiao Y, Angulo MT, Lao S, Weiss ST, Liu YY. An ecological framework to understand the efficacy of fecal microbiota transplantation. Nat Commun 2020;11:3329. [PMID: 32620839 DOI: 10.1038/s41467-020-17180-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
186 Maxson T, Mitchell DA. Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid Diagnostics. Tetrahedron 2016;72:3609-24. [PMID: 27429480 DOI: 10.1016/j.tet.2015.09.069] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
187 Kim MJ, Kim BS, Kwon JW, Ahn SE, Lee SS, Park HC, Lee BH. Risk factors for the development of Clostridium difficile colitis in a surgical ward. J Korean Surg Soc 2012;83:14-20. [PMID: 22792529 DOI: 10.4174/jkss.2012.83.1.14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
188 Chumbler NM, Rutherford SA, Zhang Z, Farrow MA, Lisher JP, Farquhar E, Giedroc DP, Spiller BW, Melnyk RA, Lacy DB. Crystal structure of Clostridium difficile toxin A. Nat Microbiol 2016;1:15002. [PMID: 27571750 DOI: 10.1038/nmicrobiol.2015.2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
189 Deng L, Tay H, Peng G, Lee JWJ, Tan KSW. Prevalence and molecular subtyping of Blastocystis in patients with Clostridium difficile infection, Singapore. Parasit Vectors 2021;14:277. [PMID: 34030712 DOI: 10.1186/s13071-021-04749-8] [Reference Citation Analysis]
190 Kociolek LK, Perdue ER, Fawley WN, Wilcox MH, Gerding DN, Johnson S. Correlation between restriction endonuclease analysis and PCR ribotyping for the identification of Clostridioides (Clostridium) difficile clinical strains. Anaerobe 2018;54:1-7. [PMID: 30009944 DOI: 10.1016/j.anaerobe.2018.07.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
191 Binyamin D, Nitzan O, Azrad M, Hamo Z, Koren O, Peretz A. In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile. Front Microbiol 2018;9:1256. [PMID: 29942295 DOI: 10.3389/fmicb.2018.01256] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
192 Azevedo MM, Pina-Vaz C, Baltazar F. Microbes and Cancer: Friends or Faux? Int J Mol Sci 2020;21:E3115. [PMID: 32354115 DOI: 10.3390/ijms21093115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
193 Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis. 2012;55:351-357. [PMID: 22523271 DOI: 10.1093/cid/cis430] [Cited by in Crossref: 139] [Cited by in F6Publishing: 132] [Article Influence: 13.9] [Reference Citation Analysis]
194 Ghose C, Eugenis I, Sun X, Edwards AN, McBride SM, Pride DT, Kelly CP, Ho DD. Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC. Emerg Microbes Infect 2016;5:e8. [PMID: 26839147 DOI: 10.1038/emi.2016.8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
195 Xie J, Horton M, Zorman J, Antonello JM, Zhang Y, Arnold BA, Secore S, Xoconostle R, Miezeiewski M, Wang S, Price CE, Thiriot D, Goerke A, Gentile MP, Skinner JM, Heinrichs JH. Development and optimization of a high-throughput assay to measure neutralizing antibodies against Clostridium difficile binary toxin. Clin Vaccine Immunol 2014;21:689-97. [PMID: 24623624 DOI: 10.1128/CVI.00038-14] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
196 Zhang D, Prabhu VS, Marcella SW. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States. Clin Infect Dis 2018;66:1326-32. [PMID: 29360950 DOI: 10.1093/cid/cix1021] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
197 Broecker F, Wegner E, Seco BMS, Kaplonek P, Bräutigam M, Ensser A, Pfister F, Daniel C, Martin CE, Mattner J, Seeberger PH. Synthetic Oligosaccharide-Based Vaccines Protect Mice from Clostridioides difficile Infections. ACS Chem Biol 2019;14:2720-8. [PMID: 31692324 DOI: 10.1021/acschembio.9b00642] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
198 Speri E, Qian Y, Janardhanan J, Masitas C, Lastochkin E, De Benedetti S, Wang M, Schroeder VA, Wolter WR, Oliver AG, Fisher JF, Mobashery S, Chang M. Structure-Activity Relationship for the Picolinamide Antibacterials that Selectively Target Clostridioides difficile. ACS Med Chem Lett 2021;12:991-5. [PMID: 34141083 DOI: 10.1021/acsmedchemlett.1c00135] [Reference Citation Analysis]
199 Bilverstone TW, Garland M, Cave RJ, Kelly ML, Tholen M, Bouley DM, Kaye P, Minton NP, Bogyo M, Kuehne SA, Melnyk RA. The glucosyltransferase activity of C. difficile Toxin B is required for disease pathogenesis. PLoS Pathog 2020;16:e1008852. [PMID: 32960931 DOI: 10.1371/journal.ppat.1008852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
200 Jeon YD, Ann HW, Lee WJ, Kim JH, Seong H, Kim JH, Ahn JY, Jeong SJ, Ku NS, Yeom JS, Yong D, Lee K, Choi JY. Characteristics of Faecal Microbiota in Korean Patients with Clostridioides difficile-associated Diarrhea. Infect Chemother 2019;51:365-75. [PMID: 31898424 DOI: 10.3947/ic.2019.51.4.365] [Reference Citation Analysis]
201 Kociolek LK, Gerding DN. Clinical Utility of Laboratory Detection of Clostridium difficile Strain BI/NAP1/027. J Clin Microbiol 2016;54:19-24. [PMID: 26511742 DOI: 10.1128/JCM.02340-15] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
202 Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34:771-785. [PMID: 25439276 DOI: 10.1016/j.cll.2014.08.008] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 9.0] [Reference Citation Analysis]
203 Hemmasi S, Czulkies BA, Schorch B, Veit A, Aktories K, Papatheodorou P. Interaction of the Clostridium difficile Binary Toxin CDT and Its Host Cell Receptor, Lipolysis-stimulated Lipoprotein Receptor (LSR). J Biol Chem 2015;290:14031-44. [PMID: 25882847 DOI: 10.1074/jbc.M115.650523] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
204 Boonma P, Spinler JK, Venable SF, Versalovic J, Tumwasorn S. Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells. BMC Microbiol 2014;14:177. [PMID: 24989059 DOI: 10.1186/1471-2180-14-177] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
205 Lee L, Cohen SH. Community-Acquired Clostridium difficile Infection: An Emerging Problem. Curr Emerg Hosp Med Rep 2013;1:149-53. [DOI: 10.1007/s40138-013-0020-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
206 Xu MQ, Cao HL, Wang WQ, Wang S, Cao XC, Yan F, Wang BM. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol 2015; 21(1): 102-111 [PMID: 25574083 DOI: 10.3748/wjg.v21.i1.102] [Cited by in CrossRef: 125] [Cited by in F6Publishing: 104] [Article Influence: 17.9] [Reference Citation Analysis]
207 Haran JP, Hayward G, Skinner S, Merritt C, Hoaglin DC, Hibberd PL, Lu S, Boyer EW. Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: risk of administering IV antibiotics. Am J Emerg Med 2014;32:1195-9. [PMID: 25149599 DOI: 10.1016/j.ajem.2014.07.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
208 Gutiérrez RL, Riddle MS, Porter CK. Epidemiology of Clostridium difficile infection among active duty United States military personnel (1998-2010). BMC Infect Dis 2013;13:609. [PMID: 24373384 DOI: 10.1186/1471-2334-13-609] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
209 Hung YP, Tsai PJ, Hung KH, Liu HC, Lee CI, Lin HJ, Wu YH, Wu JJ, Ko WC. Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan. PLoS One 2012;7:e42415. [PMID: 22876321 DOI: 10.1371/journal.pone.0042415] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
210 Chen D, Oezguen N, Urvil P, Ferguson C, Dann SM, Savidge TC. Regulation of protein-ligand binding affinity by hydrogen bond pairing. Sci Adv 2016;2:e1501240. [PMID: 27051863 DOI: 10.1126/sciadv.1501240] [Cited by in Crossref: 136] [Cited by in F6Publishing: 101] [Article Influence: 22.7] [Reference Citation Analysis]
211 Tariq R, Laguio-Vila M, Tahir MW, Orenstein R, Pardi DS, Khanna S. Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:1756284821994046. [PMID: 33747124 DOI: 10.1177/1756284821994046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
212 Hansen S, Nile AH, Mehta SC, Fuhrmann J, Hannoush RN. Lead Optimization Yields High Affinity Frizzled 7-Targeting Peptides That Modulate Clostridium difficile Toxin B Pathogenicity in Epithelial Cells. J Med Chem 2019;62:7739-50. [PMID: 31429553 DOI: 10.1021/acs.jmedchem.9b00500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
213 Jarchum I, Liu M, Shi C, Equinda M, Pamer EG. Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis. Infect Immun. 2012;80:2989-2996. [PMID: 22689818 DOI: 10.1128/iai.00448-12] [Cited by in Crossref: 99] [Cited by in F6Publishing: 76] [Article Influence: 9.9] [Reference Citation Analysis]
214 Unger M, Eichhoff AM, Schumacher L, Strysio M, Menzel S, Schwan C, Alzogaray V, Zylberman V, Seman M, Brandner J, Rohde H, Zhu K, Haag F, Mittrücker HW, Goldbaum F, Aktories K, Koch-Nolte F. Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT. Sci Rep 2015;5:7850. [PMID: 25597743 DOI: 10.1038/srep07850] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
215 Gutelius D, Hokeness K, Logan SM, Reid CW. Functional analysis of SleC from Clostridium difficile: an essential lytic transglycosylase involved in spore germination. Microbiology (Reading) 2014;160:209-16. [PMID: 24140647 DOI: 10.1099/mic.0.072454-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
216 Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012;87:1106-1117. [PMID: 23127735 DOI: 10.1016/j.mayocp.2012.07.016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 9.1] [Reference Citation Analysis]
217 Amedei A, Capasso C, Nannini G, Supuran CT. Microbiota, Bacterial Carbonic Anhydrases, and Modulators of Their Activity: Links to Human Diseases? Mediators Inflamm 2021;2021:6926082. [PMID: 34803517 DOI: 10.1155/2021/6926082] [Reference Citation Analysis]
218 Septimus EJ, Albrecht HH, Solomon G, Shea T, Guenin EP. Extended-Release Guaifenesin/Pseudoephedrine Hydrochloride for Symptom Relief in Support of a Wait-and-See Approach for the Treatment of Acute Upper Respiratory Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Study. Curr Ther Res Clin Exp 2017;84:54-61. [PMID: 28761581 DOI: 10.1016/j.curtheres.2017.04.004] [Reference Citation Analysis]
219 Gregory AL, Pensinger DA, Hryckowian AJ. A short chain fatty acid-centric view of Clostridioides difficile pathogenesis. PLoS Pathog 2021;17:e1009959. [PMID: 34673840 DOI: 10.1371/journal.ppat.1009959] [Reference Citation Analysis]
220 Kociolek LK, Gerding DN, Hecht DW, Ozer EA. Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106. Microbes Infect 2018;20:245-53. [PMID: 29391259 DOI: 10.1016/j.micinf.2018.01.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
221 Rojo D, Gosalbes MJ, Ferrari R, Pérez-Cobas AE, Hernández E, Oltra R, Buesa J, Latorre A, Barbas C, Ferrer M, Moya A. Clostridium difficile heterogeneously impacts intestinal community architecture but drives stable metabolome responses. ISME J 2015;9:2206-20. [PMID: 25756679 DOI: 10.1038/ismej.2015.32] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
222 Cheng JW, Xiao M, Kudinha T, Xu ZP, Hou X, Sun LY, Zhang L, Fan X, Kong F, Xu YC. The First Two Clostridium difficile Ribotype 027/ST1 Isolates Identified in Beijing, China-an Emerging Problem or a Neglected Threat? Sci Rep 2016;6:18834. [PMID: 26740150 DOI: 10.1038/srep18834] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
223 Paredes-Sabja D, Shen A, Sorg JA. Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol 2014;22:406-16. [PMID: 24814671 DOI: 10.1016/j.tim.2014.04.003] [Cited by in Crossref: 226] [Cited by in F6Publishing: 195] [Article Influence: 28.3] [Reference Citation Analysis]
224 Zackular JP, Moore JL, Jordan AT, Juttukonda LJ, Noto MJ, Nicholson MR, Crews JD, Semler MW, Zhang Y, Ware LB, Washington MK, Chazin WJ, Caprioli RM, Skaar EP. Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection. Nat Med 2016;22:1330-4. [PMID: 27668938 DOI: 10.1038/nm.4174] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 18.7] [Reference Citation Analysis]
225 Guttenberg G, Papatheodorou P, Genisyuerek S, Lü W, Jank T, Einsle O, Aktories K. Inositol hexakisphosphate-dependent processing of Clostridium sordellii lethal toxin and Clostridium novyi alpha-toxin. J Biol Chem 2011;286:14779-86. [PMID: 21385871 DOI: 10.1074/jbc.M110.200691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
226 Johanesen PA, Mackin KE, Hutton ML, Awad MM, Larcombe S, Amy JM, Lyras D. Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance. Genes (Basel) 2015;6:1347-60. [PMID: 26703737 DOI: 10.3390/genes6041347] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
227 Buchan BW, Mackey TL, Daly JA, Alger G, Denys GA, Peterson LR, Kehl SC, Ledeboer NA. Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. J Clin Microbiol. 2012;50:3932-3936. [PMID: 23015667 DOI: 10.1128/jcm.02083-12] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
228 Song Y, Garg S, Girotra M, Maddox C, von Rosenvinge EC, Dutta A, Dutta S, Fricke WF. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One. 2013;8:e81330. [PMID: 24303043 DOI: 10.1371/journal.pone.0081330] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 13.9] [Reference Citation Analysis]
229 Vickers R, Robinson N, Best E, Echols R, Tillotson G, Wilcox M. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections. BMC Infect Dis 2015;15:91. [PMID: 25880933 DOI: 10.1186/s12879-015-0759-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
230 Ser HL, Letchumanan V, Goh BH, Wong SH, Lee LH. The Use of Fecal Microbiome Transplant in Treating Human Diseases: Too Early for Poop? Front Microbiol 2021;12:519836. [PMID: 34054740 DOI: 10.3389/fmicb.2021.519836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
231 Dmitrieva NV, Klyasova GA, Bakulina NV, Sukhina MA, Zhuravel SV, Belousova EA, Ivashkin VT, Goryunov SV, Prokhorovich EA, Kameneva TR, Samsonov AA, Yakovenko AV, Kazakov SV. Prevalence of Clostridium Difficile-Associated Diarrhoea in Hospitalised Patients (Results of a Russian Prospective Multicentre Study). Infect Dis Ther 2018;7:523-34. [PMID: 30203332 DOI: 10.1007/s40121-018-0209-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
232 Kang JK, Hwang JS, Nam HJ, Ahn KJ, Seok H, Kim SK, Yun EY, Pothoulakis C, Lamont JT, Kim H. The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity. Antimicrob Agents Chemother 2011;55:4850-7. [PMID: 21807975 DOI: 10.1128/AAC.00177-11] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
233 Tenover FC, Tickler IA, Persing DH. Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrob Agents Chemother 2012;56:2929-32. [PMID: 22411613 DOI: 10.1128/AAC.00220-12] [Cited by in Crossref: 85] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
234 Khanna S, Pardi DS. Clostridium difficile infection: management strategies for a difficult disease. Therap Adv Gastroenterol 2014;7:72-86. [PMID: 24587820 DOI: 10.1177/1756283X13508519] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
235 Maldarelli GA, De Masi L, von Rosenvinge EC, Carter M, Donnenberg MS. Identification, immunogenicity, and cross-reactivity of type IV pilin and pilin-like proteins from Clostridium difficile. Pathog Dis 2014;71:302-14. [PMID: 24550179 DOI: 10.1111/2049-632X.12137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
236 He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45:109-113. [PMID: 23222960 DOI: 10.1038/ng.2478] [Cited by in Crossref: 481] [Cited by in F6Publishing: 435] [Article Influence: 48.1] [Reference Citation Analysis]
237 Kociolek LK, Gerding DN. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol. 2016;13:150-160. [PMID: 26860266 DOI: 10.1038/nrgastro.2015.220] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 13.7] [Reference Citation Analysis]
238 Elahi M, Nakayama-Imaohji H, Hashimoto M, Tada A, Yamasaki H, Nagao T, Kuwahara T. The Human Gut Microbe Bacteroides thetaiotaomicron Suppresses Toxin Release from Clostridium difficile by Inhibiting Autolysis. Antibiotics (Basel) 2021;10:187. [PMID: 33671889 DOI: 10.3390/antibiotics10020187] [Reference Citation Analysis]
239 Nerandzic MM, Donskey CJ. A Quaternary Ammonium Disinfectant Containing Germinants Reduces Clostridium difficile Spores on Surfaces by Inducing Susceptibility to Environmental Stressors. Open Forum Infect Dis 2016;3:ofw196. [PMID: 28066792 DOI: 10.1093/ofid/ofw196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
240 Hsu LY, Tan TY, Koh TH, Kwa AL, Krishnan P, Tee NW, Jureen R. Decline in Clostridium difficile-associated disease rates in Singapore public hospitals, 2006 to 2008. BMC Res Notes 2011;4:77. [PMID: 21429188 DOI: 10.1186/1756-0500-4-77] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
241 de Blank P, Zaoutis T, Fisher B, Troxel A, Kim J, Aplenc R. Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr. 2013;163:699-705.e1. [PMID: 23477996 DOI: 10.1016/j.jpeds.2013.01.062] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
242 Zacharioudakis IM, Zervou FN, Shehadeh F, Mylona EK, Mylonakis E. Association of Community Factors with Hospital-onset Clostridioides (Clostridium) difficile Infection: A Population Based U.S.-wide Study. EClinicalMedicine 2019;8:12-9. [PMID: 31193719 DOI: 10.1016/j.eclinm.2019.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
243 Zhang Y, Li S, Yang Z, Shi L, Yu H, Salerno-Goncalves R, Saint Fleur A, Feng H. Cysteine Protease-Mediated Autocleavage of Clostridium difficile Toxins Regulates Their Proinflammatory Activity. Cell Mol Gastroenterol Hepatol 2018;5:611-25. [PMID: 29930981 DOI: 10.1016/j.jcmgh.2018.01.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
244 Banerjee P, Merkel GJ, Bhunia AK. Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog 2009;1:8. [PMID: 19397787 DOI: 10.1186/1757-4749-1-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
245 Kim H, Rhee SH, Pothoulakis C, LaMont JT. Clostridium difficile toxin A binds colonocyte Src causing dephosphorylation of focal adhesion kinase and paxillin. Exp Cell Res 2009;315:3336-44. [PMID: 19481075 DOI: 10.1016/j.yexcr.2009.05.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
246 Chiu CW, Tsai PJ, Lee CC, Ko WC, Hung YP. Application of Microbiome Management in Therapy for Clostridioides difficile Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents. Pathogens 2021;10:649. [PMID: 34073695 DOI: 10.3390/pathogens10060649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Pérez-Cobas AE, Moya A, Gosalbes MJ, Latorre A. Colonization Resistance of the Gut Microbiota against Clostridium difficile. Antibiotics (Basel) 2015;4:337-57. [PMID: 27025628 DOI: 10.3390/antibiotics4030337] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
248 Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis. 2013;57:555-561. [PMID: 23704121 DOI: 10.1093/cid/cit346] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 8.4] [Reference Citation Analysis]
249 Maldarelli GA, Piepenbrink KH, Scott AJ, Freiberg JA, Song Y, Achermann Y, Ernst RK, Shirtliff ME, Sundberg EJ, Donnenberg MS, von Rosenvinge EC. Type IV pili promote early biofilm formation by Clostridium difficile. Pathog Dis 2016;74:ftw061. [PMID: 27369898 DOI: 10.1093/femspd/ftw061] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
250 Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist 2014;7:63-72. [PMID: 24669194 DOI: 10.2147/IDR.S46780] [Cited by in Crossref: 22] [Cited by in F6Publishing: 66] [Article Influence: 2.8] [Reference Citation Analysis]
251 Kim J, Seo MR, Kang JO, Choi TY, Pai H. Clinical and Microbiologic Characteristics of Clostridium difficile Infection Caused by Binary Toxin Producing Strain in Korea. Infect Chemother 2013;45:175-83. [PMID: 24265965 DOI: 10.3947/ic.2013.45.2.175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
252 Alverdy J, Gilbert J, DeFazio JR, Sadowsky MJ, Chang EB, Morowitz MJ, Teitelbaum DH. Proceedings of the 2013 A.S.P.E.N. Research workshop: the interface between nutrition and the gut microbiome: implications and applications for human health [corrected]. JPEN J Parenter Enteral Nutr 2014;38:167-78. [PMID: 24379111 DOI: 10.1177/0148607113517904] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
253 Gomceli U, Vangala S, Zeana C, Kelly PJ, Singh M. An Unusual Case of Ototoxicity with Use of Oral Vancomycin. Case Rep Infect Dis 2018;2018:2980913. [PMID: 30057833 DOI: 10.1155/2018/2980913] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
254 Harvala H, Alm E, Åkerlund T, Rizzardi K. Emergence and spread of moxifloxacin-resistant Clostridium difficile ribotype 231 in Sweden between 2006 and 2015. New Microbes New Infect 2016;14:58-66. [PMID: 27752322 DOI: 10.1016/j.nmni.2016.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
255 Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes 2011;2:326-34. [PMID: 22198617 DOI: 10.4161/gmic.19142] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 10.6] [Reference Citation Analysis]
256 Wilcox MH, Chalmers JD, Nord CE, Freeman J, Bouza E. Role of cephalosporins in the era of Clostridium difficile infection. J Antimicrob Chemother 2017;72:1-18. [PMID: 27659735 DOI: 10.1093/jac/dkw385] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
257 Koon HW, Wang J, Mussatto CC, Ortiz C, Lee EC, Tran DH, Chen X, Kelly CP, Pothoulakis C. Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-κB Activity. Antimicrob Agents Chemother 2018;62:e01513-17. [PMID: 29038278 DOI: 10.1128/AAC.01513-17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
258 Schneider KM, Wirtz TH, Kroy D, Albers S, Neumann UP, Strowig T, Sellge G, Trautwein C. Successful Fecal Microbiota Transplantation in a Patient with Severe Complicated Clostridium difficile Infection after Liver Transplantation. Case Rep Gastroenterol 2018;12:76-84. [PMID: 29606940 DOI: 10.1159/000481937] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
259 Zhao X, Bender F, Shukla R, Kang JJ, Caro-Aguilar I, Laterza OF. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection. Bioanalysis 2016;8:611-23. [PMID: 26964649 DOI: 10.4155/bio-2015-0033] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
260 Radhakrishnan GK, Splitter GA. Modulation of host microtubule dynamics by pathogenic bacteria. Biomol Concepts 2012;3:571-80. [PMID: 23585820 DOI: 10.1515/bmc-2012-0030] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
261 Martinez FJ, Leffler DA, Kelly CP. Clostridium difficile outbreaks: prevention and treatment strategies. Risk Manag Healthc Policy. 2012;5:55-64. [PMID: 22826646 DOI: 10.2147/rmhp.s13053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
262 Gallagher JC, Reilly JP, Navalkele B, Downham G, Haynes K, Trivedi M. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother 2015;59:7007-10. [PMID: 26324268 DOI: 10.1128/AAC.00939-15] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 4.1] [Reference Citation Analysis]
263 Kirkwood KA, Gulack BC, Iribarne A, Bowdish ME, Greco G, Mayer ML, O'Sullivan K, Gelijns AC, Fumakia N, Ghanta RK, Raiten JM, Lala A, Ladowski JS, Blackstone EH, Parides MK, Moskowitz AJ, Horvath KA. A multi-institutional cohort study confirming the risks of Clostridium difficile infection associated with prolonged antibiotic prophylaxis. J Thorac Cardiovasc Surg 2018;155:670-678.e1. [PMID: 29102205 DOI: 10.1016/j.jtcvs.2017.09.089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
264 Vargason AM, Anselmo AC. Clinical translation of microbe-based therapies: Current clinical landscape and preclinical outlook. Bioeng Transl Med 2018;3:124-37. [PMID: 30065967 DOI: 10.1002/btm2.10093] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
265 Velez DR, Ahmeti M. Clostridioides difficile Enteritis Induced Anastomotic Rupture: A Case Report and Literature Review. Case Rep Surg 2020;2020:9794823. [PMID: 32607274 DOI: 10.1155/2020/9794823] [Reference Citation Analysis]
266 Staley C, Kaiser T, Vaughn BP, Graiziger C, Hamilton MJ, Kabage AJ, Khoruts A, Sadowsky MJ. Durable Long-Term Bacterial Engraftment following Encapsulated Fecal Microbiota Transplantation To Treat Clostridium difficile Infection. mBio 2019;10:e01586-19. [PMID: 31337728 DOI: 10.1128/mBio.01586-19] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 10.7] [Reference Citation Analysis]
267 Leshem A, Horesh N, Elinav E. Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome. Front Immunol 2019;10:1341. [PMID: 31258528 DOI: 10.3389/fimmu.2019.01341] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
268 Sehgal K, Yadav D, Khanna S. The interplay of Clostridioides difficile infection and inflammatory bowel disease. Therap Adv Gastroenterol 2021;14:17562848211020285. [PMID: 34104215 DOI: 10.1177/17562848211020285] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
269 Cammarota G, Ianiro G, Bibbò S, Gasbarrini A. Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation? Intern Emerg Med. 2014;9:365-373. [PMID: 24664520 DOI: 10.1007/s11739-014-1069-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 7.9] [Reference Citation Analysis]
270 Doona CJ, Feeherry FE, Setlow B, Wang S, Li W, Nichols FC, Talukdar PK, Sarker MR, Li YQ, Shen A, Setlow P. Effects of High-Pressure Treatment on Spores of Clostridium Species. Appl Environ Microbiol 2016;82:5287-97. [PMID: 27316969 DOI: 10.1128/AEM.01363-16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
271 Na X, Kelly C. The vermiform appendix and recurrent Clostridium difficile infection: a curious connection. Clin Gastroenterol Hepatol 2011;9:1017-9. [PMID: 21893132 DOI: 10.1016/j.cgh.2011.08.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
272 Duburcq T, Parmentier-Decrucq E, Poissy J, Mathieu D. Pseudomembranous colitis due to Clostridium difficile as a cause of perineal necrotising fasciitis. BMJ Case Rep 2013;2013:bcr2012008153. [PMID: 23345501 DOI: 10.1136/bcr-2012-008153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
273 Kim J, Pai H, Seo MR, Kang JO. Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital. J Korean Med Sci 2011;26:1258-64. [PMID: 22022175 DOI: 10.3346/jkms.2011.26.10.1258] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
274 Kumar N, Miyajima F, He M, Roberts P, Swale A, Ellison L, Pickard D, Smith G, Molyneux R, Dougan G, Parkhill J, Wren BW, Parry CM, Pirmohamed M, Lawley TD. Genome-Based Infection Tracking Reveals Dynamics of Clostridium difficile Transmission and Disease Recurrence. Clin Infect Dis 2016;62:746-52. [PMID: 26683317 DOI: 10.1093/cid/civ1031] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
275 Kantamaneni VK, Gurram KC, Kulkarni A. Clostridium difficile extraintestinal abscess: a rare complication. BMJ Case Rep 2017;2017:bcr-2017-219957. [PMID: 28536228 DOI: 10.1136/bcr-2017-219957] [Reference Citation Analysis]
276 Puri AW, Lupardus PJ, Deu E, Albrow VE, Garcia KC, Bogyo M, Shen A. Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB. Chem Biol 2010;17:1201-11. [PMID: 21095570 DOI: 10.1016/j.chembiol.2010.09.011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
277 Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8:1-6. [PMID: 24516694 DOI: 10.5009/gnl.2014.8.1.1] [Cited by in Crossref: 133] [Cited by in F6Publishing: 114] [Article Influence: 16.6] [Reference Citation Analysis]
278 Papatheodorou P, Carette JE, Bell GW, Schwan C, Guttenberg G, Brummelkamp TR, Aktories K. Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc Natl Acad Sci U S A 2011;108:16422-7. [PMID: 21930894 DOI: 10.1073/pnas.1109772108] [Cited by in Crossref: 129] [Cited by in F6Publishing: 115] [Article Influence: 11.7] [Reference Citation Analysis]
279 Deng H, Yang S, Zhang Y, Qian K, Zhang Z, Liu Y, Wang Y, Bai Y, Fan H, Zhao X, Zhi F. Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation. Front Microbiol 2018;9:2976. [PMID: 30619112 DOI: 10.3389/fmicb.2018.02976] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
280 Zanella Terrier MC, Simonet ML, Bichard P, Frossard JL. Recurrent Clostridium difficile infections: The importance of the intestinal microbiota. World J Gastroenterol 2014; 20(23): 7416-7423 [PMID: 24966611 DOI: 10.3748/wjg.v20.i23.7416] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
281 Hing TC, Ho S, Shih DQ, Ichikawa R, Cheng M, Chen J, Chen X, Law I, Najarian R, Kelly CP, Gallo RL, Targan SR, Pothoulakis C, Koon HW. The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut 2013;62:1295-305. [PMID: 22760006 DOI: 10.1136/gutjnl-2012-302180] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.9] [Reference Citation Analysis]
282 Greenberg SA, Youngster I, Cohen NA, Livovsky DM, Strahilevitz J, Israeli E, Melzer E, Paz K, Fliss-Isakov N, Maharshak N. Five years of fecal microbiota transplantation - an update of the Israeli experience. World J Gastroenterol 2018; 24(47): 5403-5414 [PMID: 30598584 DOI: 10.3748/wjg.v24.i47.5403] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
283 Chen X, Lamont JT. Overview of Clostridium difficile infection: implications for China. Gastroenterol Rep (Oxf) 2013;1:153-8. [PMID: 24759960 DOI: 10.1093/gastro/got029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
284 Trzasko A, Leeds JA, Praestgaard J, Lamarche MJ, McKenney D. Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother 2012;56:4459-62. [PMID: 22644020 DOI: 10.1128/AAC.06355-11] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
285 Mezoff EA, Cohen MB. Acid suppression and the risk of Clostridium difficile infection. J Pediatr 2013;163:627-30. [PMID: 23759424 DOI: 10.1016/j.jpeds.2013.04.047] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
286 Sharma SK, Yip C, Esposito EX, Sharma PV, Simon MP, Abel-Santos E, Firestine SM. The Design, Synthesis, and Characterizations of Spore Germination Inhibitors Effective against an Epidemic Strain of Clostridium difficile. J Med Chem 2018;61:6759-78. [PMID: 30004695 DOI: 10.1021/acs.jmedchem.8b00632] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
287 Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi DS, Kashyap P. Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther 2016;44:715-27. [PMID: 27481036 DOI: 10.1111/apt.13750] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 10.3] [Reference Citation Analysis]
288 Winston JA, Theriot CM. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract. Anaerobe 2016;41:44-50. [PMID: 27163871 DOI: 10.1016/j.anaerobe.2016.05.003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
289 Ahmetagic S, Salkic N, Ahmetagic A, Custovic A, Tihic N, Smajlovic J, Porobic-Jahic H. Clostridium difficile infection in hospitalized patients at university clinical center tuzla, bosnia and herzegovina: a 4 year experience. Mater Sociomed 2013;25:153-7. [PMID: 24167425 DOI: 10.5455/msm.2013.25.153-157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
290 Sehgal K, Khanna S. Immune response against Clostridioides difficile and translation to therapy. Therap Adv Gastroenterol 2021;14:17562848211014817. [PMID: 33995585 DOI: 10.1177/17562848211014817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
291 Pan Z, Zhang Y, Luo J, Li D, Zhou Y, He L, Yang Q, Dong M, Tao L. Functional analyses of epidemic Clostridioides difficile toxin B variants reveal their divergence in utilizing receptors and inducing pathology. PLoS Pathog 2021;17:e1009197. [PMID: 33507919 DOI: 10.1371/journal.ppat.1009197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
292 Quesada-Gómez C, López-Ureña D, Chumbler N, Kroh HK, Castro-Peña C, Rodríguez C, Orozco-Aguilar J, González-Camacho S, Rucavado A, Guzmán-Verri C, Lawley TD, Lacy DB, Chaves-Olarte E. Analysis of TcdB Proteins within the Hypervirulent Clade 2 Reveals an Impact of RhoA Glucosylation on Clostridium difficile Proinflammatory Activities. Infect Immun 2016;84:856-65. [PMID: 26755157 DOI: 10.1128/IAI.01291-15] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
293 Scaria J, Chen JW, Useh N, He H, McDonough SP, Mao C, Sobral B, Chang YF. Comparative nutritional and chemical phenome of Clostridium difficile isolates determined using phenotype microarrays. Int J Infect Dis 2014;27:20-5. [PMID: 25130165 DOI: 10.1016/j.ijid.2014.06.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
294 Speri E, Janardhanan J, Masitas C, Schroeder VA, Lastochkin E, Wolter WR, Fisher JF, Mobashery S, Chang M. Discovery of a Potent Picolinamide Antibacterial Active against Clostridioides difficile. ACS Infect Dis 2020;6:2362-8. [PMID: 32786277 DOI: 10.1021/acsinfecdis.0c00479] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
295 Neumann H, Günther C, Vieth M, Grauer M, Wittkopf N, Mudter J, Becker C, Schoerner C, Atreya R, Neurath MF. Confocal laser endomicroscopy for in vivo diagnosis of Clostridium difficile associated colitis - a pilot study. PLoS One. 2013;8:e58753. [PMID: 23527018 DOI: 10.1371/journal.pone.0058753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
296 Calu V, Toma EA, Enciu O, Miron A. Clostridium difficile Infection and Colorectal Surgery: Is There Any Risk? Medicina (Kaunas) 2019;55:E683. [PMID: 31658780 DOI: 10.3390/medicina55100683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
297 LaFrance ME, Farrow MA, Chandrasekaran R, Sheng J, Rubin DH, Lacy DB. Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity. Proc Natl Acad Sci U S A 2015;112:7073-8. [PMID: 26038560 DOI: 10.1073/pnas.1500791112] [Cited by in Crossref: 98] [Cited by in F6Publishing: 80] [Article Influence: 14.0] [Reference Citation Analysis]
298 Solanky D, Pardi DS, Loftus EV, Khanna S. Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflamm Bowel Dis 2019;25:610-9. [PMID: 30260451 DOI: 10.1093/ibd/izy291] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
299 Winston JA, Rivera AJ, Cai J, Thanissery R, Montgomery SA, Patterson AD, Theriot CM. Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids. Infect Immun 2020;88:e00045-20. [PMID: 32205405 DOI: 10.1128/IAI.00045-20] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
300 Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, Kracker H, Charef P, Cornely OA. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection. Antimicrob Agents Chemother. 2015;59:6266-6273. [PMID: 26248357 DOI: 10.1128/aac.00504-15] [Cited by in Crossref: 55] [Cited by in F6Publishing: 25] [Article Influence: 7.9] [Reference Citation Analysis]
301 Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58:892-900. [PMID: 24277020 DOI: 10.1128/aac.01830-13] [Cited by in Crossref: 66] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
302 Shanahan F. Therapeutic implications of manipulating and mining the microbiota. J Physiol 2009;587:4175-9. [PMID: 19505978 DOI: 10.1113/jphysiol.2009.174649] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
303 Peretz A, Tkhawkho L, Pastukh N, Brodsky D, Halevi CN, Nitzan O. Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection. BMC Infect Dis. 2016;16:309. [PMID: 27334992 DOI: 10.1186/s12879-016-1618-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
304 Orenstein R, Litin SC. Clinical pearls in infectious diseases. Mayo Clin Proc 2010;85:172-5. [PMID: 20118393 DOI: 10.4065/mcp.2009.0465] [Reference Citation Analysis]
305 Chen K, Zhu Y, Zhang Y, Hamza T, Yu H, Saint Fleur A, Galen J, Yang Z, Feng H. A probiotic yeast-based immunotherapy against Clostridioides difficile infection. Sci Transl Med 2020;12:eaax4905. [PMID: 33115949 DOI: 10.1126/scitranslmed.aax4905] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
306 Lemon KP, Armitage GC, Relman DA, Fischbach MA. Microbiota-targeted therapies: an ecological perspective. Sci Transl Med 2012;4:137rv5. [PMID: 22674555 DOI: 10.1126/scitranslmed.3004183] [Cited by in Crossref: 163] [Cited by in F6Publishing: 147] [Article Influence: 16.3] [Reference Citation Analysis]
307 Xiao XY, Zhao XP, Tan ZJ. Clostridium difficile-associated intestinal diseases. Shijie Huaren Xiaohua Zazhi 2015; 23(10): 1539-1545 [DOI: 10.11569/wcjd.v23.i10.1539] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
308 Mehta SR, Yen EF. Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy. Transl Res 2021;230:197-207. [PMID: 33278650 DOI: 10.1016/j.trsl.2020.11.013] [Reference Citation Analysis]
309 Ali M, Ananthakrishnan AN, Ahmad S, Kumar N, Kumar G, Saeian K. Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. Liver Transpl. 2012;18:972-978. [PMID: 22505356 DOI: 10.1002/lt.23449] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
310 Nasser H, Munie S, Shakaroun D, Ivanics T, Nalamati S, Killu K. Clostridium difficile Enteritis after Total Abdominal Colectomy for Ulcerative Colitis. Case Rep Crit Care 2019;2019:2987682. [PMID: 30863646 DOI: 10.1155/2019/2987682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
311 Torti A, Lossani A, Savi L, Focher F, Wright GE, Brown NC, Xu WC. Clostridium difficile DNA polymerase IIIC: basis for activity of antibacterial compounds. Curr Enzym Inhib 2011;7:147-53. [PMID: 22844265 DOI: 10.2174/157340811798807597] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
312 Gerber GK, Onderdonk AB, Bry L. Inferring dynamic signatures of microbes in complex host ecosystems. PLoS Comput Biol 2012;8:e1002624. [PMID: 22876171 DOI: 10.1371/journal.pcbi.1002624] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
313 Hota SS, Achonu C, Crowcroft NS, Harvey BJ, Lauwers A, Gardam MA. Determining mortality rates attributable to Clostridium difficile infection. Emerg Infect Dis 2012;18:305-7. [PMID: 22305427 DOI: 10.3201/eid1802.101611] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
314 Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010;74:417-33. [PMID: 20805405 DOI: 10.1128/MMBR.00016-10] [Cited by in Crossref: 2572] [Cited by in F6Publishing: 1013] [Article Influence: 214.3] [Reference Citation Analysis]
315 Fimlaid KA, Jensen O, Donnelly ML, Francis MB, Sorg JA, Shen A. Identification of a Novel Lipoprotein Regulator of Clostridium difficile Spore Germination. PLoS Pathog 2015;11:e1005239. [PMID: 26496694 DOI: 10.1371/journal.ppat.1005239] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
316 Mitchell BG, Gardner A. Prolongation of length of stay and Clostridium difficile infection: a review of the methods used to examine length of stay due to healthcare associated infections. Antimicrob Resist Infect Control 2012;1:14. [PMID: 22958238 DOI: 10.1186/2047-2994-1-14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
317 Alam MZ, Wu X, Mascio C, Chesnel L, Hurdle JG. Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile. Antimicrob Agents Chemother 2015;59:5165-70. [PMID: 26055381 DOI: 10.1128/AAC.01087-15] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
318 Pacyga K, Razim A, Martirosian G, Aptekorz M, Szuba A, Gamian A, Myc A, Górska S. The Bioinformatic and In Vitro Studies of Clostridioides Difficile Aminopeptidase M24 Revealed the Immunoreactive KKGIK Peptide. Cells 2020;9:E1146. [PMID: 32392707 DOI: 10.3390/cells9051146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
319 Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, Figueiredo C. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67:226-236. [PMID: 29102920 DOI: 10.1136/gutjnl-2017-314205] [Cited by in Crossref: 199] [Cited by in F6Publishing: 184] [Article Influence: 39.8] [Reference Citation Analysis]
320 Wang WJ, Gray S, Sison C, Arramraju S, John BK, Hussain SA, Kim SH, Mehta P, Rubin M. Low vitamin D level is an independent predictor of poor outcomes in Clostridium difficile-associated diarrhea. Therap Adv Gastroenterol 2014;7:14-9. [PMID: 24381644 DOI: 10.1177/1756283X13502838] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
321 Freedberg DE, Abrams JA. Clostridium difficile infection in the community: Are proton pump inhibitors to blame? World J Gastroenterol 2013; 19(40): 6710-6713 [PMID: 24187445 DOI: 10.3748/wjg.v19.i40.6710] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
322 Padua D, Pothoulakis C. Novel approaches to treating Clostridium difficile-associated colitis. Expert Rev Gastroenterol Hepatol 2016;10:193-204. [PMID: 26643655 DOI: 10.1586/17474124.2016.1109444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
323 Manek K, Williams V, Callery S, Daneman N. Reducing the risk of severe complications among patients with Clostridium difficile infection. Can J Gastroenterol 2011;25:368-72. [PMID: 21876858 DOI: 10.1155/2011/153020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
324 Staley C, Kelly CR, Brandt LJ, Khoruts A, Sadowsky MJ. Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation. mBio 2016;7:e01965-16. [PMID: 27999162 DOI: 10.1128/mBio.01965-16] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
325 Hung YP, Huang IH, Lin HJ, Tsai BY, Liu HC, Liu HC, Lee JC, Wu YH, Tsai PJ, Ko WC. Predominance of Clostridium difficile Ribotypes 017 and 078 among Toxigenic Clinical Isolates in Southern Taiwan. PLoS One 2016;11:e0166159. [PMID: 27861606 DOI: 10.1371/journal.pone.0166159] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
326 Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, Chen K, Yu H, Tremblay JM, Chen X, Piepenbrink KH, Sundberg EJ, Kelly CP, Bai G, Shoemaker CB, Feng H. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis 2014;210:964-72. [PMID: 24683195 DOI: 10.1093/infdis/jiu196] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
327 Lee PC, Chang TE, Wang YP, Lee KC, Lin YT, Chiou JJ, Huang CW, Yang UC, Li FY, Huang HC, Wu CY, Huang YH, Hou MC. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection. J Formos Med Assoc 2021:S0929-6646(21)00498-8. [PMID: 34836663 DOI: 10.1016/j.jfma.2021.11.001] [Reference Citation Analysis]
328 Schenck LP, Beck PL, MacDonald JA. Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection. World J Gastrointest Pathophysiol 2015; 6(4): 169-180 [PMID: 26600975 DOI: 10.4291/wjgp.v6.i4.169] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
329 Gupta P, Zhang Z, Sugiman-Marangos SN, Tam J, Raman S, Julien JP, Kroh HK, Lacy DB, Murgolo N, Bekkari K, Therien AG, Hernandez LD, Melnyk RA. Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants. J Biol Chem 2017;292:17290-301. [PMID: 28842504 DOI: 10.1074/jbc.M117.806687] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
330 Kociolek LK, Ozer EA, Gerding DN, Hecht DW, Patel SJ, Hauser AR. Whole-genome analysis reveals the evolution and transmission of an MDR DH/NAP11/106 Clostridium difficile clone in a paediatric hospital. J Antimicrob Chemother 2018;73:1222-9. [PMID: 29342270 DOI: 10.1093/jac/dkx523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
331 Stein BE, Greenough WB 3rd, Mears SC. Management and prevention of recurrent clostridium difficile infection in patients after total joint arthroplasty: a review. Geriatr Orthop Surg Rehabil 2012;3:157-63. [PMID: 23569710 DOI: 10.1177/2151458513479023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
332 Mullish BH, Williams HR. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med (Lond) 2018;18:237-41. [PMID: 29858434 DOI: 10.7861/clinmedicine.18-3-237] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
333 Williams MD, Ha CY, Ciorba MA. Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations. J Clin Gastroenterol 2010;44:631-6. [PMID: 20216432 DOI: 10.1097/MCG.0b013e3181d47f5b] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
334 Shao X, AbdelKhalek A, Abutaleb NS, Velagapudi UK, Yoganathan S, Seleem MN, Talele TT. Chemical Space Exploration around Thieno[3,2-d]pyrimidin-4(3H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors. J Med Chem 2019;62:9772-91. [PMID: 31584822 DOI: 10.1021/acs.jmedchem.9b01198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
335 Friedman-Korn T, Livovsky DM, Maharshak N, Aviv Cohen N, Paz K, Bar-Gil Shitrit A, Goldin E, Koslowsky B. Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients. Dig Dis Sci. 2018;63:198-203. [PMID: 29134299 DOI: 10.1007/s10620-017-4833-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
336 Schwartz R, Guichard A, Franc NC, Roy S, Bier E. A Drosophila Model for Clostridium difficile Toxin CDT Reveals Interactions with Multiple Effector Pathways. iScience 2020;23:100865. [PMID: 32058973 DOI: 10.1016/j.isci.2020.100865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
337 Brain D, Yakob L, Barnett A, Riley T, Clements A, Halton K, Graves N. Economic evaluation of interventions designed to reduce Clostridium difficile infection. PLoS One 2018;13:e0190093. [PMID: 29298322 DOI: 10.1371/journal.pone.0190093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
338 Yakob L, Riley TV, Paterson DL, Marquess J, Magalhaes RJ, Furuya-Kanamori L, Clements AC. Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic strains: an epidemiological model. Sci Rep 2015;5:12666. [PMID: 26218654 DOI: 10.1038/srep12666] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
339 de Araújo Junqueira AF, Dias AA, Vale ML, Spilborghs GM, Bossa AS, Lima BB, Carvalho AF, Guerrant RL, Ribeiro RA, Brito GA. Adenosine deaminase inhibition prevents Clostridium difficile toxin A-induced enteritis in mice. Infect Immun 2011;79:653-62. [PMID: 21115723 DOI: 10.1128/IAI.01159-10] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
340 Ochfeld E, Balmert LC, Patel SJ, Muller WJ, Kociolek LK. Risk factors for Clostridioides (Clostridium) difficile infection following solid organ transplantation in children. Transpl Infect Dis 2019;21:e13149. [PMID: 31332916 DOI: 10.1111/tid.13149] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
341 Walkty A, Lagacé-Wiens PR, Manickam K, Adam H, Pieroni P, Hoban D, Karlowsky JA, Alfa M. Evaluation of an algorithmic approach in comparison with the Illumigene assay for laboratory diagnosis of Clostridium difficile infection. J Clin Microbiol 2013;51:1152-7. [PMID: 23363829 DOI: 10.1128/JCM.03203-12] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
342 Sundaram V, May FP, Manne V, Saab S. Effects of Clostridium difficile infection in patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 2014;12:1745-52.e2. [PMID: 24681081 DOI: 10.1016/j.cgh.2014.02.041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
343 Xie J, Zorman J, Indrawati L, Horton M, Soring K, Antonello JM, Zhang Y, Secore S, Miezeiewski M, Wang S, Kanavage AD, Skinner JM, Rogers I, Bodmer JL, Heinrichs JH. Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins. Clin Vaccine Immunol 2013;20:517-25. [PMID: 23389929 DOI: 10.1128/CVI.00549-12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
344 Hung YP, Lin HJ, Wu TC, Liu HC, Lee JC, Lee CI, Wu YH, Wan L, Tsai PJ, Ko WC. Risk factors of fecal toxigenic or non-toxigenic Clostridium difficile colonization: impact of Toll-like receptor polymorphisms and prior antibiotic exposure. PLoS One 2013;8:e69577. [PMID: 23936050 DOI: 10.1371/journal.pone.0069577] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
345 Hung YP, Tsai PJ, Lee YT, Tang HJ, Lin HJ, Liu HC, Lee JC, Tsai BY, Hsueh PR, Ko WC. Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan. Infect Drug Resist 2018;11:1197-203. [PMID: 30147348 DOI: 10.2147/IDR.S162874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
346 Iwamori M, Iwamori Y, Adachi S, Nomura T. Changes in bacterial glycolipids as an index of intestinal lactobacilli and epithelial glycolipids in the digestive tracts of mice after administration of penicillin and streptomycin. Glycoconj J 2013;30:889-97. [PMID: 23996013 DOI: 10.1007/s10719-013-9494-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
347 Chen S, Gu H, Sun C, Wang H, Wang J. Rapid detection of Clostridium difficile toxins and laboratory diagnosis of Clostridium difficile infections. Infection 2017;45:255-62. [PMID: 27601055 DOI: 10.1007/s15010-016-0940-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
348 Knafl D, Vossen MG, Gerges C, Lobmeyr E, Karolyi M, Wagner L, Thalhammer F. Hypoalbuminemia as predictor of recurrence of Clostridium difficile infection. Wien Klin Wochenschr 2019;131:68-74. [PMID: 30617709 DOI: 10.1007/s00508-018-1432-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
349 Yin JC, Fei CH, Lo YC, Hsiao YY, Chang JC, Nix JC, Chang YY, Yang LW, Huang IH, Wang S. Structural Insights into Substrate Recognition by Clostridium difficile Sortase. Front Cell Infect Microbiol 2016;6:160. [PMID: 27921010 DOI: 10.3389/fcimb.2016.00160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
350 Džunková M, D'Auria G, Xu H, Huang J, Duan Y, Moya A, Kelly CP, Chen X. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection. Front Cell Infect Microbiol 2016;6:119. [PMID: 27757389 DOI: 10.3389/fcimb.2016.00119] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
351 Yakob L, Riley TV, Paterson DL, Clements AC. Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC Infect Dis 2013;13:376. [PMID: 23947736 DOI: 10.1186/1471-2334-13-376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
352 Novack L, Kogan S, Gimpelevich L, Howell M, Borer A, Kelly CP, Leffler DA, Novack V. Acid suppression therapy does not predispose to Clostridium difficile infection: the case of the potential bias. PLoS One 2014;9:e110790. [PMID: 25343667 DOI: 10.1371/journal.pone.0110790] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
353 Fimlaid KA, Bond JP, Schutz KC, Putnam EE, Leung JM, Lawley TD, Shen A. Global analysis of the sporulation pathway of Clostridium difficile. PLoS Genet 2013;9:e1003660. [PMID: 23950727 DOI: 10.1371/journal.pgen.1003660] [Cited by in Crossref: 147] [Cited by in F6Publishing: 116] [Article Influence: 16.3] [Reference Citation Analysis]
354 Matte I, Lane D, Côté E, Asselin AE, Fortier LC, Asselin C, Piché A. Antiapoptotic proteins Bcl-2 and Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells. Infect Immun 2009;77:5400-10. [PMID: 19797069 DOI: 10.1128/IAI.00485-09] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
355 Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, Nie W, Kumar R, Tzipori S, Wang J. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun. 2012;80:2678-2688. [PMID: 22615245 DOI: 10.1128/iai.00215-12] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
356 Nylund CM, Goudie A, Garza JM, Fairbrother G, Cohen MB. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med. 2011;165:451-457. [PMID: 21199971 DOI: 10.1001/archpediatrics.2010.282] [Cited by in Crossref: 130] [Cited by in F6Publishing: 114] [Article Influence: 11.8] [Reference Citation Analysis]
357 Lin CJ, Wade TJ, Hilborn ED. Flooding and Clostridium difficile Infection: A Case-Crossover Analysis. Int J Environ Res Public Health 2015;12:6948-64. [PMID: 26090609 DOI: 10.3390/ijerph120606948] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
358 Huang JH, Wu CW, Lien SP, Leng CH, Hsiao KN, Liu SJ, Chen HW, Siu LK, Chong P. Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J Biomed Sci 2015;22:65. [PMID: 26245825 DOI: 10.1186/s12929-015-0171-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
359 Na'amnih W, Carmeli Y, Asato V, Goren S, Adler A, Cohen D, Muhsen K. Enhanced Humoral Immune Responses against Toxin A and B of Clostridium difficile is Associated with a Milder Disease Manifestation. J Clin Med 2020;9:E3241. [PMID: 33050453 DOI: 10.3390/jcm9103241] [Reference Citation Analysis]
360 Di Bella S, Drapeau C, García-Almodóvar E, Petrosillo N. Fecal microbiota transplantation: the state of the art. Infect Dis Rep. 2013;5:e13. [PMID: 24470963 DOI: 10.4081/idr.2013.e13] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
361 Kim PK, Huh HC, Cohen HW, Feinberg EJ, Ahmad S, Coyle C, Teperman S, Boothe H. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect (Larchmt) 2013;14:532-9. [PMID: 23560732 DOI: 10.1089/sur.2012.158] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
362 Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol. 2016;9:229-239. [PMID: 26929784 DOI: 10.1177/1756283x15607414] [Cited by in Crossref: 142] [Cited by in F6Publishing: 70] [Article Influence: 23.7] [Reference Citation Analysis]
363 Huang B, Jin D, Zhang J, Sun JY, Wang X, Stiles J, Xu X, Kamboj M, Babady NE, Tang YW. Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool. J Clin Microbiol 2014;52:1105-11. [PMID: 24452160 DOI: 10.1128/JCM.02601-13] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
364 Haney EF, Straus SK, Hancock REW. Reassessing the Host Defense Peptide Landscape. Front Chem 2019;7:43. [PMID: 30778385 DOI: 10.3389/fchem.2019.00043] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 41.3] [Reference Citation Analysis]
365 Rehman A, Heinsen FA, Koenen ME, Venema K, Knecht H, Hellmig S, Schreiber S, Ott SJ. Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine. BMC Microbiol 2012;12:47. [PMID: 22452835 DOI: 10.1186/1471-2180-12-47] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
366 Shivashankar R, Khanna S, Kammer PP, Scott Harmsen W, Zinsmeister AR, Baddour LM, Pardi DS. Clinical predictors of recurrent Clostridium difficile infection in out-patients. Aliment Pharmacol Ther 2014;40:518-22. [PMID: 25039269 DOI: 10.1111/apt.12864] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.4] [Reference Citation Analysis]
367 Tenover FC, Akerlund T, Gerding DN, Goering RV, Boström T, Jonsson AM, Wong E, Wortman AT, Persing DH. Comparison of strain typing results for Clostridium difficile isolates from North America. J Clin Microbiol 2011;49:1831-7. [PMID: 21389155 DOI: 10.1128/JCM.02446-10] [Cited by in Crossref: 80] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
368 Pokhrel A, Poudel A, Castro KB, Celestine MJ, Oludiran A, Rinehold AJ, Resek AM, Mhanna MA, Purcell EB. The (p)ppGpp Synthetase RSH Mediates Stationary-Phase Onset and Antibiotic Stress Survival in Clostridioides difficile. J Bacteriol 2020;202:e00377-20. [PMID: 32661079 DOI: 10.1128/JB.00377-20] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
369 Martin MJ, Clare S, Goulding D, Faulds-Pain A, Barquist L, Browne HP, Pettit L, Dougan G, Lawley TD, Wren BW. The agr locus regulates virulence and colonization genes in Clostridium difficile 027. J Bacteriol 2013;195:3672-81. [PMID: 23772065 DOI: 10.1128/JB.00473-13] [Cited by in Crossref: 75] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]
370 Lefrancois D, Leung S. Advancing into the Community. The American Journal of Medicine 2012;125:657-60. [DOI: 10.1016/j.amjmed.2012.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
371 Lai H, Huang C, Cai J, Ye J, She J, Zheng Y, Wang L, Wei Y, Fang W, Wang X, Tang YW, Luo Y, Jin D. Simultaneous detection and characterization of toxigenic Clostridium difficile directly from clinical stool specimens. Front Med 2018;12:196-205. [PMID: 29058256 DOI: 10.1007/s11684-017-0560-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
372 Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044-1049. [PMID: 21871249 DOI: 10.1016/j.cgh.2011.08.014] [Cited by in Crossref: 575] [Cited by in F6Publishing: 503] [Article Influence: 52.3] [Reference Citation Analysis]
373 Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, Galera Lopez MM, Orellana-miguel MÁ, Díaz-garcía CV, Cortijo-cascajares S, Cortes-funes H, Agulló-ortuño MT. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer 2015;23:1569-77. [DOI: 10.1007/s00520-014-2506-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
374 Justin S, Antony B, Shenoy KV, Boloor R. Prevalence of clostridium difficile among paediatric patients in a tertiary care hospital, coastal karnataka, South India. J Clin Diagn Res 2015;9:DC04-7. [PMID: 25859452 DOI: 10.7860/JCDR/2015/11000.5534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
375 Wei L, Ratnayake L, Phillips G, McGuigan CC, Morant SV, Flynn RW, Mackenzie IS, MacDonald TM. Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. Br J Clin Pharmacol 2017;83:1298-308. [PMID: 28054368 DOI: 10.1111/bcp.13205] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
376 Ballard TE, Wang X, Olekhnovich I, Koerner T, Seymour C, Hoffman PS, Macdonald TL. Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide. Bioorg Med Chem Lett 2010;20:3537-9. [PMID: 20488706 DOI: 10.1016/j.bmcl.2010.04.126] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
377 Weis S, Grimm M. [Nosocomial diarrhea]. Internist (Berl) 2011;52:167-77. [PMID: 21279316 DOI: 10.1007/s00108-010-2789-9] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
378 Li X, Gao X, Hu H, Xiao Y, Li D, Yu G, Yu D, Zhang T, Wang Y. Clinical Efficacy and Microbiome Changes Following Fecal Microbiota Transplantation in Children With Recurrent Clostridium Difficile Infection. Front Microbiol 2018;9:2622. [PMID: 30450088 DOI: 10.3389/fmicb.2018.02622] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
379 Na JY, Park JM, Lee KS, Kang JO, Oh SH, Kim YJ. Clinical Characteristics of Symptomatic Clostridium difficile Infection in Children: Conditions as Infection Risks and Whether Probiotics Is Effective. Pediatr Gastroenterol Hepatol Nutr. 2014;17:232-238. [PMID: 25587523 DOI: 10.5223/pghn.2014.17.4.232] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
380 Ueda C, Tateda K, Horikawa M, Kimura S, Ishii Y, Nomura K, Yamada K, Suematsu T, Inoue Y, Ishiguro M, Miyairi S, Yamaguchi K. Anti-Clostridium difficile potential of tetramic acid derivatives from Pseudomonas aeruginosa quorum-sensing autoinducers. Antimicrob Agents Chemother 2010;54:683-8. [PMID: 19917748 DOI: 10.1128/AAC.00702-09] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
381 Antonio AC, Maccari JG, Seabra A, Tonietto TF. Clostridium difficile and cytomegalovirus colitis coinfection after bariatric surgery: case report. Arq Bras Cir Dig 2013;26 Suppl 1:85-7. [PMID: 24463907 DOI: 10.1590/s0102-67202013000600019] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
382 Madisch A. ["Since antibiotic therapy I suffer from chronic diarrhea"]. MMW Fortschr Med 2013;155:38-9. [PMID: 23923313 DOI: 10.1007/s15006-013-1012-z] [Reference Citation Analysis]
383 Patel I, Wungjiranirun M, Theethira T, Villafuerte-Galvez J, Castillo N, Akbari M, Alonso CD, Leffler DA, Kelly CP. Lack of adherence to SHEA-IDSA treatment guidelines for Clostridium difficile infection is associated with increased mortality. J Antimicrob Chemother 2017;72:574-81. [PMID: 28115504 DOI: 10.1093/jac/dkw423] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
384 Tariq R, Weatherly RM, Kammer PP, Pardi DS, Khanna S. Experience and Outcomes at a Specialized Clostridium difficile Clinical Practice. Mayo Clin Proc Innov Qual Outcomes 2017;1:49-56. [PMID: 30225401 DOI: 10.1016/j.mayocpiqo.2017.05.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
385 Dineen SP, Bailey SH, Pham TH, Huerta S. Clostridium difficile enteritis: A report of two cases and systematic literature review. World J Gastrointest Surg 2013; 5(3): 37-42 [PMID: 23556059 DOI: 10.4240/wjgs.v5.i3.37] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
386 Johnston PF, Gerding DN, Knight KL. Protection from Clostridium difficile infection in CD4 T Cell- and polymeric immunoglobulin receptor-deficient mice. Infect Immun 2014;82:522-31. [PMID: 24478068 DOI: 10.1128/IAI.01273-13] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
387 Gupta A, Pardi DS, Baddour LM, Khanna S. Outcomes in children with Clostridium difficile infection: results from a nationwide survey. Gastroenterol Rep (Oxf) 2016;4:293-8. [PMID: 27081152 DOI: 10.1093/gastro/gow007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
388 Soto Ocaña J, Bayard NU, Zackular JP. Pain killers: the interplay between nonsteroidal anti-inflammatory drugs and Clostridioides difficile infection. Curr Opin Microbiol 2021;65:167-74. [PMID: 34894543 DOI: 10.1016/j.mib.2021.11.011] [Reference Citation Analysis]
389 Jiang CY, Li M, Tan MH. Clostridium difficile infection: epidemiology and control measurements. Shijie Huaren Xiaohua Zazhi 2010; 18(34): 3667-3671 [DOI: 10.11569/wcjd.v18.i34.3667] [Reference Citation Analysis]
390 Adams HM, Li X, Mascio C, Chesnel L, Palmer KL. Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species. Antimicrob Agents Chemother 2015;59:4139-47. [PMID: 25941217 DOI: 10.1128/AAC.00526-15] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
391 Vanzant EL, Ozrazgat-Baslanti T, Liu H, Malik S, Davis R, Lanz J, Miggins MV, Gentile LF, Cuenca A, Cuenca AG, Lottenberg L, Moore FA, Ang DN, Bihorac A, Efron PA. Clostridium difficile Infections after Blunt Trauma: A Different Patient Population? Surg Infect (Larchmt) 2015;16:421-7. [PMID: 26207402 DOI: 10.1089/sur.2013.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
392 Sykes E, McDonald P, Flanagan PK. Corticosteroids in the Treatment of Pseudomembranous Colitis: A Report of 3 Cases. Gastroenterology Res. 2012;5:211-214. [PMID: 27785209 DOI: 10.4021/gr469w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
393 Dirweesh A, Alvarez C, Khan M, Ambreen B, Yelisetti R, Hamiz SF, Zia S, Tahir M, DeBari VA, Christmas D, Wallach S. Lack of Association Between the Clinical Outcome of Clostridium difficile Infection and Current Steroids Use. Gastroenterology Res 2017;10:116-9. [PMID: 28496532 DOI: 10.14740/gr822w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
394 Dotson KM, Aitken SL, Sofjan AK, Shah DN, Aparasu RR, Garey KW. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect 2018;146:1101-5. [PMID: 29739486 DOI: 10.1017/S0950268818001036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
395 Ryder AB, Huang Y, Li H, Zheng M, Wang X, Stratton CW, Xu X, Tang YW. Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system. J Clin Microbiol 2010;48:4129-34. [PMID: 20720023 DOI: 10.1128/JCM.01104-10] [Cited by in Crossref: 66] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
396 Wang S, Shen A, Setlow P, Li YQ. Characterization of the Dynamic Germination of Individual Clostridium difficile Spores Using Raman Spectroscopy and Differential Interference Contrast Microscopy. J Bacteriol 2015;197:2361-73. [PMID: 25939833 DOI: 10.1128/JB.00200-15] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
397 Oka K, Osaki T, Hanawa T, Kurata S, Sugiyama E, Takahashi M, Tanaka M, Taguchi H, Kamiya S. Establishment of an Endogenous Clostridium difficile Rat Infection Model and Evaluation of the Effects of Clostridium butyricum MIYAIRI 588 Probiotic Strain. Front Microbiol 2018;9:1264. [PMID: 29967595 DOI: 10.3389/fmicb.2018.01264] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
398 Jang MO, An JH, Jung SI, Park KH. Refractory Clostridium difficile Infection Cured With Fecal Microbiota Transplantation in Vancomycin-Resistant Enterococcus Colonized Patient. Intest Res 2015;13:80-4. [PMID: 25691847 DOI: 10.5217/ir.2015.13.1.80] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
399 Hirshon JM, Thompson AD, Limbago B, McDonald LC, Bonkosky M, Heimer R, Meek J, Mai V, Braden C. Clostridium difficile infection in outpatients, Maryland and Connecticut, USA, 2002-2007. Emerg Infect Dis 2011;17:1946-9. [PMID: 22000379 DOI: 10.3201/eid1710.110069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
400 Huang JH, Shen ZQ, Lien SP, Hsiao KN, Leng CH, Chen CC, Siu LK, Chong PC. Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A. PLoS One 2015;10:e0135045. [PMID: 26271033 DOI: 10.1371/journal.pone.0135045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
401 Fettucciari K, Marconi P, Marchegiani A, Fruganti A, Spaterna A, Bassotti G. Invisible steps for a global endemy: molecular strategies adopted by Clostridioides difficile. Therap Adv Gastroenterol 2021;14:17562848211032797. [PMID: 34413901 DOI: 10.1177/17562848211032797] [Reference Citation Analysis]
402 Russo HM, Rathkey J, Boyd-Tressler A, Katsnelson MA, Abbott DW, Dubyak GR. Active Caspase-1 Induces Plasma Membrane Pores That Precede Pyroptotic Lysis and Are Blocked by Lanthanides. J Immunol 2016;197:1353-67. [PMID: 27385778 DOI: 10.4049/jimmunol.1600699] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 15.0] [Reference Citation Analysis]
403 Dineen SS, McBride SM, Sonenshein AL. Integration of metabolism and virulence by Clostridium difficile CodY. J Bacteriol 2010;192:5350-62. [PMID: 20709897 DOI: 10.1128/JB.00341-10] [Cited by in Crossref: 120] [Cited by in F6Publishing: 93] [Article Influence: 10.0] [Reference Citation Analysis]
404 Li S, Shi L, Yang Z, Zhang Y, Perez-Cordon G, Huang T, Ramsey J, Oezguen N, Savidge TC, Feng H. Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis. Infect Immun 2015;83:502-13. [PMID: 25404023 DOI: 10.1128/IAI.02316-14] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
405 Norsigian CJ, Danhof HA, Brand CK, Oezguen N, Midani FS, Palsson BO, Savidge TC, Britton RA, Spinler JK, Monk JM. Systems biology analysis of the Clostridioides difficile core-genome contextualizes microenvironmental evolutionary pressures leading to genotypic and phenotypic divergence. NPJ Syst Biol Appl 2020;6:31. [PMID: 33082337 DOI: 10.1038/s41540-020-00151-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
406 Shi XR, Chen BY, Lin WZ, Li YL, Wang YL, Liu Y, Huang JJ, Zhang WW, Ma XX, Shao S, Li RG, Duan SZ. Microbiota in Gut, Oral Cavity, and Mitral Valves Are Associated With Rheumatic Heart Disease. Front Cell Infect Microbiol 2021;11:643092. [PMID: 33768014 DOI: 10.3389/fcimb.2021.643092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
407 Larson AM, Fung AM, Fang FC. Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol. 2010;48:124-130. [PMID: 19923482 DOI: 10.1128/jcm.00734-09] [Cited by in Crossref: 84] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
408 Gooyit M, Janda KD. Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile. Sci Rep 2016;6:33642. [PMID: 27633064 DOI: 10.1038/srep33642] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
409 Hashash JG, Binion DG. Managing Clostridium difficile in inflammatory bowel disease (IBD). Curr Gastroenterol Rep. 2014;16:393. [PMID: 24838421 DOI: 10.1007/s11894-014-0393-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
410 Khoruts A, Weingarden AR. Emergence of fecal microbiota transplantation as an approach to repair disrupted microbial gut ecology. Immunol Lett. 2014;162:77-81. [PMID: 25106113 DOI: 10.1016/j.imlet.2014.07.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
411 Berdichevski T, Keller N, Rahav G, Bar-Meir S, Eliakim R, Ben-Horin S. The impact of pseudomembrane formation on the outcome of Clostridium difficile-associated disease. Infection 2013;41:969-77. [PMID: 23709307 DOI: 10.1007/s15010-013-0473-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
412 Di Bella S, Friedrich AW, García-Almodóvar E, Gallone MS, Taglietti F, Topino S, Galati V, Johnson E, D'Arezzo S, Petrosillo N. Clostridium difficile infection among hospitalized HIV-infected individuals: epidemiology and risk factors: results from a case-control study (2002-2013). BMC Infect Dis 2015;15:194. [PMID: 25899507 DOI: 10.1186/s12879-015-0932-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
413 Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013;108:1794-801. [PMID: 24060760 DOI: 10.1038/ajg.2013.333] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 8.0] [Reference Citation Analysis]
414 Tamma PD, Sandora TJ. Clostridium difficile Infection in Children: Current State and Unanswered Questions. J Pediatric Infect Dis Soc 2012;1:230-43. [PMID: 23687578 DOI: 10.1093/jpids/pis071] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
415 Willems J, Hermans E, Schelstraete P, Depuydt P, De Cock P. Optimizing the Use of Antibiotic Agents in the Pediatric Intensive Care Unit: A Narrative Review. Paediatr Drugs 2021;23:39-53. [PMID: 33174101 DOI: 10.1007/s40272-020-00426-y] [Reference Citation Analysis]
416 Saab S, Alper T, Sernas E, Pruthi P, Alper MA, Sundaram V. Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis. Dig Dis Sci 2015;60:3124-9. [DOI: 10.1007/s10620-015-3707-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
417 Majeed A, Larriva MM, Iftikhar A, Mushtaq A, Campbell P, Nadeem Malik M, Rafae A, Zar MA, Kamal A, Lakhani M, Khalid NR, Zangeneh TT, Anwer F. A Single-Center Experience and Literature Review of Management Strategies for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Patients. Infect Dis Clin Pract (Baltim Md) 2020;28:10-5. [PMID: 33424210 DOI: 10.1097/ipc.0000000000000798] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
418 Ota KV, McGowan KL. Clostridium difficile testing algorithms using glutamate dehydrogenase antigen and C. difficile toxin enzyme immunoassays with C. difficile nucleic acid amplification testing increase diagnostic yield in a tertiary pediatric population. J Clin Microbiol 2012;50:1185-8. [PMID: 22259201 DOI: 10.1128/JCM.05620-11] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
419 Mintz M, Khair S, Grewal S, LaComb JF, Park J, Channer B, Rajapakse R, Bucobo JC, Buscaglia JM, Monzur F, Chawla A, Yang J, Robertson CE, Frank DN, Li E. Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis. PLoS One. 2018;13:e0190997. [PMID: 29385143 DOI: 10.1371/journal.pone.0190997] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
420 Ciorba MA. A gastroenterologist’s guide to probiotics. Clin Gastroenterol Hepatol. 2012;10:960-968. [PMID: 22504002 DOI: 10.1016/j.cgh.2012.03.024] [Cited by in Crossref: 85] [Cited by in F6Publishing: 63] [Article Influence: 8.5] [Reference Citation Analysis]
421 Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014;306:G310-G319. [PMID: 24284963 DOI: 10.1152/ajpgi.00282.2013] [Cited by in Crossref: 236] [Cited by in F6Publishing: 220] [Article Influence: 26.2] [Reference Citation Analysis]
422 Suzuki K, Nakaoka S, Fukuda S, Masuya H. Energy landscape analysis elucidates the multistability of ecological communities across environmental gradients. Ecol Monogr 2021;91. [DOI: 10.1002/ecm.1469] [Reference Citation Analysis]
423 Lübbert C, John E, von Müller L. Clostridium difficile infection: guideline-based diagnosis and treatment. Dtsch Arztebl Int. 2014;111:723-731. [PMID: 25404529 DOI: 10.3238/arztebl.2014.0723] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
424 Smith AB, Soto Ocana J, Zackular JP. From Nursery to Nursing Home: Emerging Concepts in Clostridioides difficile Pathogenesis. Infect Immun 2020;88:e00934-19. [PMID: 32122939 DOI: 10.1128/IAI.00934-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
425 Theriot CM, Young VB. Interactions Between the Gastrointestinal Microbiome and Clostridium difficile. Annu Rev Microbiol 2015;69:445-61. [PMID: 26488281 DOI: 10.1146/annurev-micro-091014-104115] [Cited by in Crossref: 163] [Cited by in F6Publishing: 135] [Article Influence: 27.2] [Reference Citation Analysis]
426 Cheung SW, Li KK. Fulminant Pseudomembranous Colitis Presenting as Sigmoid Stricture and Severe Polyposis with Clinical Response to Intracolonic Vancomycin. Case Rep Med 2016;2016:4609824. [PMID: 27034681 DOI: 10.1155/2016/4609824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
427 Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014;306:G310-G319. [PMID: 24284963 DOI: 10.1152/ajpgi.00282] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
428 Weinstein N, Garten B, Vainer J, Minaya D, Czaja K. Managing the Microbiome: How the Gut Influences Development and Disease. Nutrients 2020;13:E74. [PMID: 33383647 DOI: 10.3390/nu13010074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
429 Oshima H, Yamazaki T, Benner L, Miki T, Michon I, Wojtkowski T, Kaibara A, Mujais S. Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects. Clin Drug Investig 2015;35:375-84. [PMID: 25972286 DOI: 10.1007/s40261-015-0291-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
430 Kreimeyer I, Euler F, Marckscheffel A, Tatge H, Pich A, Olling A, Schwarz J, Just I, Gerhard R. Autoproteolytic cleavage mediates cytotoxicity of Clostridium difficile toxin A. Naunyn Schmiedebergs Arch Pharmacol 2011;383:253-62. [PMID: 21046073 DOI: 10.1007/s00210-010-0574-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
431 Farooq PD, Urrunaga NH, Tang DM, von Rosenvinge EC. Pseudomembranous colitis. Dis Mon. 2015;61:181-206. [PMID: 25769243 DOI: 10.1016/j.disamonth.2015.01.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
432 Yu H, Chen K, Wu J, Yang Z, Shi L, Barlow LL, Aronoff DM, Garey KW, Savidge TC, von Rosenvinge EC, Kelly CP, Feng H. Identification of toxemia in patients with Clostridium difficile infection. PLoS One 2015;10:e0124235. [PMID: 25885671 DOI: 10.1371/journal.pone.0124235] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
433 Shin S, Kim M, Kim M, Lim H, Kim H, Lee K, Chong Y. Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection. Ann Lab Med. 2012;32:355-358. [PMID: 22950071 DOI: 10.3343/alm.2012.32.5.355] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
434 Koon HW, Ho S, Hing TC, Cheng M, Chen X, Ichikawa Y, Kelly CP, Pothoulakis C. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum. Antimicrob Agents Chemother 2014;58:4642-50. [PMID: 24890583 DOI: 10.1128/AAC.02783-14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
435 Frisbee AL, Petri WA Jr. Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection. Trends Mol Med 2020;26:496-507. [PMID: 32359480 DOI: 10.1016/j.molmed.2020.01.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
436 Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. The application of ecological theory toward an understanding of the human microbiome. Science 2012;336:1255-62. [PMID: 22674335 DOI: 10.1126/science.1224203] [Cited by in Crossref: 802] [Cited by in F6Publishing: 685] [Article Influence: 80.2] [Reference Citation Analysis]
437 Larocque M, Chénard T, Najmanovich R. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors. BMC Syst Biol 2014;8:117. [PMID: 25315994 DOI: 10.1186/s12918-014-0117-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
438 Mezoff E, Mann EA, Hart KW, Lindsell CJ, Cohen MB. Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population. J Pediatr Gastroenterol Nutr. 2011;52:437-441. [PMID: 21407116 DOI: 10.1097/mpg.0b013e3181f97209] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
439 Romano MR, Leuzzi R, Cappelletti E, Tontini M, Nilo A, Proietti D, Berti F, Costantino P, Adamo R, Scarselli M. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity. Toxins (Basel) 2014;6:1385-96. [PMID: 24759173 DOI: 10.3390/toxins6041385] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
440 Gilbert J, Leslie J, Putler R, Weiner S, Standke A, Penkevich A, Keidan M, Young VB, Rao K. Anti-toxin antibody is not associated with recurrent Clostridium difficile infection. Anaerobe 2021;67:102299. [PMID: 33227427 DOI: 10.1016/j.anaerobe.2020.102299] [Reference Citation Analysis]
441 Warren CA, Li Y, Calabrese GM, Freire RS, Zaja-Milatovic S, van Opstal E, Figler RA, Linden J, Guerrant RL. Contribution of adenosine A(2B) receptors in Clostridium difficile intoxication and infection. Infect Immun 2012;80:4463-73. [PMID: 23045479 DOI: 10.1128/IAI.00782-12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
442 Silva-García O, Valdez-Alarcón JJ, Baizabal-Aguirre VM. Wnt/β-Catenin Signaling as a Molecular Target by Pathogenic Bacteria. Front Immunol 2019;10:2135. [PMID: 31611869 DOI: 10.3389/fimmu.2019.02135] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
443 Lim HW, Schuster IP, Rajapakse R, Monzur F, Khan S, Sultan K. The impact of corticosteroid use on inpatients with inflammatory bowel disease and positive polymerase chain reaction for Clostridium difficile. Intest Res 2019;17:244-52. [PMID: 30739437 DOI: 10.5217/ir.2018.00101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
444 Bouillaut L, Self WT, Sonenshein AL. Proline-dependent regulation of Clostridium difficile Stickland metabolism. J Bacteriol 2013;195:844-54. [PMID: 23222730 DOI: 10.1128/JB.01492-12] [Cited by in Crossref: 84] [Cited by in F6Publishing: 60] [Article Influence: 8.4] [Reference Citation Analysis]
445 Aktories K. Bacterial protein toxins that modify host regulatory GTPases. Nat Rev Microbiol 2011;9:487-98. [PMID: 21677684 DOI: 10.1038/nrmicro2592] [Cited by in Crossref: 203] [Cited by in F6Publishing: 175] [Article Influence: 18.5] [Reference Citation Analysis]
446 Zhang Y, Huang GM. Clostridium difficile infection in patients with inflammatory bowel disease: An update. Shijie Huaren Xiaohua Zazhi 2013; 21(23): 2308-2314 [DOI: 10.11569/wcjd.v21.i23.2308] [Reference Citation Analysis]
447 Martinez C, Edwards J, Hassoun A. Commercialized fecal microbiota transplantation provides efficacious treatment of Clostridium difficile infection. Infect Dis (Lond) 2018;50:864-7. [PMID: 30265170 DOI: 10.1080/23744235.2018.1500709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
448 Hu Y, Xiao HY, He C, Lv NH, Zhu L. Fecal microbiota transplantation as an effective initial therapy for pancreatitis complicated with severe Clostridium difficile infection: A case report. World J Clin Cases 2019; 7(17): 2597-2604 [PMID: 31559298 DOI: 10.12998/wjcc.v7.i17.2597] [Reference Citation Analysis]
449 Shin JY, Ko EJ, Lee SH, Shin JB, Kim SI, Kwon KS, Kim HG, Shin YW, Bang BW. Refractory pseudomembranous colitis that was treated successfully with colonoscopic fecal microbial transplantation. Intest Res 2016;14:83-8. [PMID: 26884739 DOI: 10.5217/ir.2016.14.1.83] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
450 Hong HA, Hitri K, Hosseini S, Kotowicz N, Bryan D, Mawas F, Wilkinson AJ, van Broekhoven A, Kearsey J, Cutting SM. Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile. Infect Immun 2017;85:e01060-16. [PMID: 28167669 DOI: 10.1128/IAI.01060-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
451 Warn P, Thommes P, Sattar A, Corbett D, Flattery A, Zhang Z, Black T, Hernandez LD, Therien AG. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin. Antimicrob Agents Chemother 2016;60:6471-82. [PMID: 27527088 DOI: 10.1128/AAC.00974-16] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
452 Lee CC, Lee JC, Chiu CW, Tsai PJ, Ko WC, Hung YP. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection. Microbiol Spectr 2021;9:e0079921. [PMID: 34668727 DOI: 10.1128/Spectrum.00799-21] [Reference Citation Analysis]
453 Jeon YD, Hong N, Kim JH, Park SH, Kim SB, Song IJ, Ann HW, Ahn JY, Kim SB, Ku NS, Lee K, Yong D, Kim JM, Choi JY. Fecal Transplantation using a Nasoenteric Tube during an Initial Episode of Severe Clostridium difficile Infection. Infect Chemother 2016;48:31-5. [PMID: 27104013 DOI: 10.3947/ic.2016.48.1.31] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
454 Zhang BZ, Cai J, Yu B, Hua Y, Lau CC, Kao RY, Sze KH, Yuen KY, Huang JD. A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile. BMC Infect Dis 2016;16:596. [PMID: 27770789 DOI: 10.1186/s12879-016-1924-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
455 Lagu T, Stefan MS, Haessler S, Higgins TL, Rothberg MB, Nathanson BH, Hannon NS, Steingrub JS, Lindenauer PK. The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis. J Hosp Med 2014;9:411-7. [PMID: 24715578 DOI: 10.1002/jhm.2199] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
456 Fang FC, Polage CR, Wilcox MH. Point-Counterpoint: What Is the Optimal Approach for Detection of Clostridium difficile Infection? J Clin Microbiol 2017;55:670-80. [PMID: 28077697 DOI: 10.1128/JCM.02463-16] [Cited by in Crossref: 77] [Cited by in F6Publishing: 35] [Article Influence: 15.4] [Reference Citation Analysis]
457 Stoltz KL, Erickson R, Staley C, Weingarden AR, Romens E, Steer CJ, Khoruts A, Sadowsky MJ, Dosa PI. Synthesis and Biological Evaluation of Bile Acid Analogues Inhibitory to Clostridium difficile Spore Germination. J Med Chem 2017;60:3451-71. [PMID: 28402634 DOI: 10.1021/acs.jmedchem.7b00295] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
458 Kabbani TA, Pallav K, Dowd SE, Villafuerte-Galvez J, Vanga RR, Castillo NE, Hansen J, Dennis M, Leffler DA, Kelly CP. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes. 2017;8:17-32. [PMID: 27973989 DOI: 10.1080/19490976.2016.1267890] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
459 Hopkins RJ, Wilson RB. Treatment of recurrent Clostridium difficile colitis: a narrative review. Gastroenterol Rep (Oxf) 2018;6:21-8. [PMID: 29479439 DOI: 10.1093/gastro/gox041] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
460 Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol. 2016;13:508-516. [PMID: 27329806 DOI: 10.1038/nrgastro.2016.98] [Cited by in Crossref: 207] [Cited by in F6Publishing: 189] [Article Influence: 34.5] [Reference Citation Analysis]
461 Nölke T, Schwan C, Lehmann F, Østevold K, Pertz O, Aktories K. Septins guide microtubule protrusions induced by actin-depolymerizing toxins like Clostridium difficile transferase (CDT). Proc Natl Acad Sci U S A 2016;113:7870-5. [PMID: 27339141 DOI: 10.1073/pnas.1522717113] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
462 AbdelKhalek A, Mohammad H, Mayhoub AS, Seleem MN. Screening for potent and selective anticlostridial leads among FDA-approved drugs. J Antibiot (Tokyo) 2020;73:392-409. [PMID: 32132676 DOI: 10.1038/s41429-020-0288-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
463 Kociolek LK, Gerding DN, Osmolski JR, Patel SJ, Snydman DR, McDermott LA, Hecht DW. Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients. Antimicrob Agents Chemother 2016;60:4896-900. [PMID: 27270275 DOI: 10.1128/AAC.00714-16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
464 Shah D, Dang MD, Hasbun R, Koo HL, Jiang ZD, DuPont HL, Garey KW. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010;8:555-64. [PMID: 20455684 DOI: 10.1586/eri.10.28] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 6.7] [Reference Citation Analysis]
465 Faris B, Blackmore A, Haboubi N. Review of medical and surgical management of Clostridium difficile infection. Tech Coloproctol 2010;14:97-105. [PMID: 20454824 DOI: 10.1007/s10151-010-0574-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
466 Bakhti SZ, Latifi-Navid S. Interplay and cooperation of Helicobacter pylori and gut microbiota in gastric carcinogenesis. BMC Microbiol 2021;21:258. [PMID: 34556055 DOI: 10.1186/s12866-021-02315-x] [Reference Citation Analysis]
467 El Feghaly RE, Stauber JL, Tarr PI, Haslam DB. Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections. J Pediatr 2013;163:1697-1704.e2. [PMID: 24011765 DOI: 10.1016/j.jpeds.2013.07.029] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
468 Chow VCY, Kwong TNY, So EWM, Ho YII, Wong SH, Lai RWM, Chan RCY. Surveillance of antibiotic resistance among common Clostridium difficile ribotypes in Hong Kong. Sci Rep 2017;7:17218. [PMID: 29222426 DOI: 10.1038/s41598-017-17523-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
469 Putnam EE, Nock AM, Lawley TD, Shen A. SpoIVA and SipL are Clostridium difficile spore morphogenetic proteins. J Bacteriol 2013;195:1214-25. [PMID: 23292781 DOI: 10.1128/JB.02181-12] [Cited by in Crossref: 89] [Cited by in F6Publishing: 63] [Article Influence: 9.9] [Reference Citation Analysis]
470 Papatheodorou P, Kindig S, Badilla-Lobo A, Fischer S, Durgun E, Thuraisingam T, Witte A, Song S, Aktories K, Chaves-Olarte E, Rodríguez C, Barth H. The Compound U18666A Inhibits the Intoxication of Cells by Clostridioides difficile Toxins TcdA and TcdB. Front Microbiol 2021;12:784856. [PMID: 34912322 DOI: 10.3389/fmicb.2021.784856] [Reference Citation Analysis]
471 Lai YH, Tsai BY, Hsu CY, Chen YH, Chou PH, Chen YL, Liu HC, Ko WC, Tsai PJ, Hung YP. The Role of Toll-Like Receptor-2 in Clostridioides difficile Infection: Evidence From a Mouse Model and Clinical Patients. Front Immunol 2021;12:691039. [PMID: 34322122 DOI: 10.3389/fimmu.2021.691039] [Reference Citation Analysis]
472 Quraishi SA, Litonjua AA, Moromizato T, Gibbons FK, Camargo CA Jr, Giovannucci E, Christopher KB. Association between prehospital vitamin D status and hospital-acquired Clostridium difficile infections. JPEN J Parenter Enteral Nutr 2015;39:47-55. [PMID: 24492311 DOI: 10.1177/0148607113511991] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
473 Le Lay C, Fernandez B, Hammami R, Ouellette M, Fliss I. On Lactococcus lactis UL719 competitivity and nisin (Nisaplin(®)) capacity to inhibit Clostridium difficile in a model of human colon. Front Microbiol 2015;6:1020. [PMID: 26441942 DOI: 10.3389/fmicb.2015.01020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
474 Kelly CR, Kunde SS, Khoruts A. Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin Gastroenterol Hepatol. 2014;12:283-288. [PMID: 24107393 DOI: 10.1016/j.cgh.2013.09.060] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
475 Knight DR, Androga GO, Ballard SA, Howden BP, Riley TV. A Phenotypically Silent vanB2 Operon Carried on a Tn1549-Like Element in Clostridium difficile. mSphere 2016;1:e00177-16. [PMID: 27536735 DOI: 10.1128/mSphere.00177-16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
476 Aitken SL, Joseph TB, Shah DN, Lasco TM, Palmer HR, DuPont HL, Xie Y, Garey KW. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014;9:e102848. [PMID: 25057871 DOI: 10.1371/journal.pone.0102848] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
477 Efron PA, Liu H, Lottenberg L, Cuenca AG, Gentile LF, Miggins MV, Bihorac A, Baker HV, Moore FA, Moldawer LL, Ang DN. A genomic analysis of Clostridium difficile infections in blunt trauma patients. J Trauma Acute Care Surg 2013;74:334-8. [PMID: 23271108 DOI: 10.1097/TA.0b013e3182789426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
478 Brotfain E, Koyfman L, Frenkel A, Peiser JG, Borer A, Gruenbaum BF, Zlotnik A, Klein M. Unusual localization of clostridium difficile infection in an isolated segment of the descending colon in a critical care patient. Case Rep Surg 2012;2012:482930. [PMID: 23316409 DOI: 10.1155/2012/482930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]